Approximate date of commencement of proposed
sale to the public: From time to time after this Registration Statement becomes effective.
If any of the securities being registered
on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box.
x
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided to Section 7(a)(2)(B) of the Securities Act.
¨
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to Section 8(a), may determine.
This Post-Effective Amendment No. 1 to
the Registration Statement (the “
Registration Statement
”) of IIOT-OXYS, Inc., a Nevada corporation (the “
Registrant
”),
is being filed to update the Registration Statement by updating the Registrant’s Financial Statements after the filing of
the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
This prospectus relates to the resale by
the selling stockholders of up to 34,673,202 shares of our common stock. Each of the selling stockholders received his, her, or
its shares either in the reverse acquisition transaction which closed on July 28, 2017, pursuant to a Consulting Agreement dated
October 1, 2017, or pursuant to a Consulting Agreement dated effective December 1, 2017.
The selling stockholders, or their pledgees,
donees, transferees or other successors-in-interest, may offer the shares of our common stock for resale in the over-the-counter
market, in isolated transactions, or in a combination of such methods of sale. The selling stockholders will sell their shares
at prevailing market prices or privately negotiated prices. There will be no underwriter’s discounts or commissions, except
for the charges to a selling shareholder for sales through a broker-dealer. All net proceeds from a sale will go to the selling
shareholder and not to us. We will pay the expenses of registering these shares.
Our stock is quoted on OTC Pink under the
symbol “ITOX.” On April 17, 2019, the last reported sale price of shares of our common stock on the OTC Pink Marketplace
was $0.09.
We have not authorized anyone to provide
you with information different from that contained in this prospectus. The selling stockholders are offering to sell, and seeking
offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or
of any sale of common stock.
For investors outside the U.S.: We have
not, and the selling stockholders have not done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the U.S. You are required to inform yourselves
about and to observe any restrictions relating to the offering of the shares of common stock and the distribution and possession
of this prospectus outside of the U.S.
Unless otherwise indicated, any reference
to “the Company”, “our company”, “we”, “us”, or “our” refers to IIOT-OXYS,
Inc., a Nevada corporation, and as applicable to its wholly owned subsidiaries, OXYS Corporation, a Nevada corporation, and HereLab,
Inc., a Delaware corporation.
We were incorporated in the State of New
Jersey on October 1, 2003 under the name of Creative Beauty Supply of New Jersey Corporation and subsequently changed our name
to Gotham Capital Holdings, Inc. on May 18, 2015. We commenced operations in the beauty supply industry as of January 1, 2004.
On November 30, 2007, our Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. From
January 1, 2009 until July 28, 2017, we had no operations and were a shell company.
On March 16, 2017, our Board of Directors
adopted resolutions, which were approved by shareholders holding a majority of our outstanding shares, to change our name to “IIOT-OXYS,
Inc.”, to authorize a change of domicile from New Jersey to Nevada, to authorize a 2017 Stock Awards Plan, and to approve
the Securities Exchange Agreement (the “
OXYS SEA
”) between the Company and OXYS Corporation (“
OXYS
”),
a Nevada corporation incorporated on August 4, 2016.
Under the terms of the OXYS SEA we acquired
100% of our issued voting shares of OXYS in exchange for 34,687,244 shares of our Common Stock. We also cancelled 1,500,000 outstanding
shares of our Common Stock and changed our management to Mr. DiBiase who also served in management of OXYS. Also, one of our principal
shareholders entered into a consulting agreement with OXYS to provide consulting services during the transition. The OXYS SEA was
effective on July 28, 2017, and our name was changed to “IIOT-OXYS, Inc.” at that time. Effective October 26, 2017,
our domicile was changed from New Jersey to Nevada.
At the present time, we have two, wholly-owned
subsidiaries which are OXYS Corporation and HereLab, Inc., through which our operations are conducted.
We develop hardware,
software and algorithms that monitor, measure and predict conditions for energy, structural, agricultural and medical applications.
We use domain-specific Artificial Intelligence to solve industrial and environmental challenges. Our engineered solutions focus
on common sense approaches to machine learning, algorithm development and hardware and software products.
Our customers
have issues and they need improvements. We design a system of hardware and software, assemble, install, monitor data and
apply our algorithms to help provide the customer insights.
We use off the
shelf components, with reconfigurable hardware architecture that adapts to a wide range of customer needs and applications.
We use open source software tools, while still creating proprietary content for customers, thereby reducing software development
time and cost. The software works with the hardware to collect data from the equipment or structure that is being monitored.
We focus on developing
insights. We develop algorithms that help our customers create insights from vast data streams. The data collected
is analyzed and reports are created for the customer. From these insights, the customer can act to improve their process,
product or structure.
Our financial statements as of and for
the years ended December 31, 2017 and 2018 were prepared assuming that we would continue as a going concern. Our significant cumulative
losses from operations as of December 31, 2018, raised substantial doubt about our ability to continue as a going concern. If the
going-concern assumption were not appropriate for our financial statements, then adjustments would be necessary to the carrying
values of the assets and liabilities, the reported revenues and expenses, and the balance sheet classifications used. Since December
31, 2018, we have continued to experience losses from operations. We have continued to fund operations primarily through the sale
of equity securities. Nevertheless, we will require additional funding to complete much of our planned operations. Our ability
to continue as a going concern is subject to our ability to generate a profit and/or obtain necessary additional funding from outside
sources, including obtaining additional funding from the sale of our securities. Except for potential proceeds from the sale of
equity in offerings by us and minimal revenues, we have no other source for additional funding. Our continued net operating losses
and stockholders’ deficiency increase the difficulty in meeting such goals and there can be no assurances that such methods
will prove successful.
We have entered into several secured loan
transactions with investors (as disclosed herein), pursuant to which the outstanding debt was secured by all our assets. In the
event we are unable to make payments, when due, on our secured debt, the lenders may foreclose on all our assets. In the event
the lenders foreclose on our assets, any stock in the Company would have no value. Our ability to make payments on secured debt,
when due, will depend upon our ability to make profit from operations and to raise additional funds through equity or debt financings.
At the moment, we have no funding commitments that have not been previously disclosed, and we may not obtain any in the future.
At the present time, we are dependent on
a small number of direct customers for most of our business, revenue and results of operations. We at present have customers in
the automotive sector, civil infrastructure sector, and the pharmaceutical sector. Two of our customers are large automotive companies,
one is a state government and one is a large pharmaceutical company. To date, these customers have generated all our revenue. We
expect to continue to experience significant customer concentration in future periods.
This customer concentration increases the
risk of quarterly fluctuations in our operating results and sensitivity to any material, adverse developments experienced by our
significant customers. Although we believe that our relationships with our major customers are good, we generally do not have long-term
contracts with any of them, which is typical of our industry. In addition, orders can be, and often are, rescheduled, canceled
and modified with little or no notice. The loss of, or any substantial reduction in sales to, any of our major direct or end customers
could have a material adverse effect on our business, financial condition and results of operations.
The limited operating history of OXYS and
HereLab in the IIoT field, makes evaluating our business and future prospects difficult. OXYS was incorporated on August 4, 2016
and HereLab was incorporated on February 27, 2017. We have not yet generated substantial income from OXYS or HereLab’s operations
and we only anticipate doing so if we are able to successfully implement our business plan. To date we have generated $206,000
from business operations. We intend in the longer term to derive further revenues from consulting services, product sales, and
software licensing. Development of our services, products, and software will require significant investment prior to commercial
introduction, and we may never be able to successfully develop or commercialize the services, products, or software in a material
way.
Our operations and performance are sensitive
to fluctuations in general economic conditions, both in the U.S. and globally. The ongoing uncertainty created by volatile currency
markets, the continued weakness in the personal computer (“
PC
”) and energy sectors, alone or in combination,
may continue to have a material adverse effect on our net sales and the financial results of our operations. In addition, we remain
concerned about the geopolitical and fiscal instability in the Middle East and some emerging markets as well as the continued volatility
of the equity markets. The impending Brexit and results of the most recent U.S. election may also create additional global economic
uncertainty. These factors could have a material adverse effect on the spending patterns of businesses including our current and
potential customers which could have a material adverse effect on our net sales and our results of operations. Other factors that
could adversely influence demand for our products include unemployment, labor and healthcare costs, access to credit, consumer
and business confidence, and other macroeconomic factors that could have a negative impact on capital investment and spending behavior.
Moreover, there can be no assurance that
our international sales will continue at existing levels or grow in accordance with our efforts to increase foreign market penetration.
In many foreign countries, particularly
in those with developing economies, it is common to engage in business practices that are prohibited by U.S. regulations applicable
to us such as the Foreign Corrupt Practices Act. Although we have policies and procedures designed to ensure compliance with these
laws, there can be no assurance that all of our employees, contractors and agents, including those based in or from countries where
practices which violate such U.S. laws may be customary, will not take actions in violation of our policies. Any violation of foreign
or U.S. laws by our employees, contractors or agents, even if such violation is prohibited by our policies, could have a material
adverse effect on our business. We must also comply with various import and export regulations. The application of these various
regulations depends on the classification of our products which can change over time as such regulations are modified or interpreted.
As a result, even if we are currently in compliance with applicable regulations, there can be no assurance that we will not have
to incur additional costs or take additional compliance actions in the future. Failure to comply with these regulations could result
in fines or termination of import and export privileges, which could have a material adverse effect on our operating results. Additionally,
the regulatory environment in some countries is very restrictive as their governments try to protect their local economy and value
of their local currency against the U.S. dollar.
Large orders may be more sensitive to changes
in the global industrial economy, may be subject to greater discount variability, lower gross margins, and may contract at a faster
pace during an economic downturn compared to smaller orders. To the extent that the amount of our net sales derived from large
orders increases in future periods, either in absolute dollars or as a percentage of our overall business, our gross margins could
decline, and we could experience greater volatility and see a greater negative impact from future downturns in the global industrial
economy. This dynamic may also have an impact on the historical seasonal pattern of our net sales and our results of operations.
These types of orders also make managing inventory levels more difficult as we have in the past and may have to in the future build
large quantities of inventory in anticipation of future demand that may not materialize.
Sales of our products are dependent on
customers in certain industries, particularly the telecommunications, semiconductor, consumer electronics, automotive, energy,
automated test equipment, power generation, federal government, state governments, defense and aerospace industries. As we have
experienced in the past, and as we may continue to experience in the future, downturns characterized by diminished product demand
in any one or more of these industries may result in decreased sales and a material adverse effect on our operating results. We
cannot predict when and to what degree contractions in these industries may occur; however, any sharp or prolonged contraction
in one or more of these industries could have a material adverse effect on our business and results of operations.
We plan to continue to make significant
investments in research, development, and marketing for new and existing products and technologies. These investments involve a
number of risks as the commercial success of such efforts depend on many factors, including our ability to anticipate and respond
to innovation, achieve the desired technological fit, and be effective with our marketing and distribution efforts. If our existing
or potential customers do not perceive our latest product offerings as providing significant new functionality or value, or if
we are late to market with a new product or technology, we may not achieve our expected return on our investments or be able recover
the costs expended to develop new product offerings, which could have a material adverse effect on our operating results. Even
if our new products are profitable, our operating margins for new products may not be as high as the margins we have experienced
historically.
The market for our products is characterized
by technological change, evolving industry standards, changes in customer needs and frequent new product introductions, and is
therefore highly dependent upon timely product innovation. Our success is dependent on our ability to successfully develop and
introduce new and enhanced products on a timely basis to replace declining revenues from older products, and on increasing penetration
in domestic and international markets. Any significant delay in releasing new products could have a material adverse effect on
the ultimate success of a product and other related products and could impede continued sales of predecessor products, any of which
could have a material adverse effect on our operating results. There can be no assurance that we will be able to introduce new
products, that our new products will achieve market acceptance or that any such acceptance will be sustained for any significant
period. Failure of our new products to achieve or sustain market acceptance could have a material adverse effect on our operating
results.
We prepare our financial statements in
conformity with accounting principles generally accepted in the U.S. These accounting principles are subject to interpretation
by the Financial Accounting Standards Board (“
FASB
”) and the Securities and Exchange Commission. A change in
these policies or interpretations could have a significant effect on our reported financial results, may retroactively affect previously
reported results, could cause unexpected financial reporting fluctuations, and may require us to make costly changes to our operational
processes and accounting systems.
The markets in which we operate are characterized
by intense competition from numerous competitors, some of which are divisions of large corporations having far greater resources
than we have, and we may face further competition from new market entrants in the future. Some examples of large and small competitors
include, but are not limited to:
Our operating results have fluctuated in
the past and may fluctuate significantly in the future due to several factors, including:
We have recently completed an acquisition
and we plan to make more in the future. Achieving the anticipated benefits of an acquisition depends upon whether the integration
of the acquired business, products or technology is accomplished efficiently and effectively. In addition, successful acquisitions
generally require, among other things, integration of product offerings, manufacturing operations and coordination of sales and
marketing and R&D efforts. These difficulties can become more challenging due to the need to coordinate geographically separated
organizations, the complexities of the technologies being integrated, and the necessities of integrating personnel with disparate
business backgrounds and combining different corporate cultures. The integration of operations following an acquisition also requires
the dedication of management resources, which may distract attention from our day-to-day business and may disrupt key R&D,
marketing or sales efforts. Our inability to successfully integrate any of our acquisitions could harm our business. The existing
products previously sold by entities we have acquired may be of a lesser quality than our products or could contain errors that
produce incorrect results on which users rely or cause failure or interruption of systems or processes that could subject us to
liability claims that could have a material adverse effect on our operating results or financial position. Furthermore, products
acquired in connection with acquisitions may not gain acceptance in our markets, and we may not achieve the anticipated or desired
benefits of such transactions.
We have experienced difficulty in securing
certain types of high-power connectors for one of our projects and anticipate that supply shortages of components used in our products,
including limited source components, can result in significant additional costs and inefficiencies in manufacturing. If we are
unsuccessful in resolving any such component shortages in a timely manner, we will experience a significant impact on the timing
of revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which would have a material adverse impact
on our operating results.
We rely on the efficient and uninterrupted
operation of complex information technology systems and networks to operate our business. We rely on a primary global center for
our management information systems and on multiple systems in branches not covered by our global center. As with any information
system, unforeseen issues may arise that could affect our ability to receive adequate, accurate and timely financial information,
which in turn could inhibit effective and timely decisions. Furthermore, it is possible that our global center for information
systems or our branch operations could experience a complete or partial shutdown. A significant system or network disruption could
be the result of new system implementations, computer viruses, cyber-attacks, security breaches, facility issues or energy blackouts.
Threats to our information technology security can take a variety of forms and individuals or groups of hackers or sophisticated
organizations including state-sponsored organizations, may take steps that pose threats to our customers and our infrastructure.
If we were to experience a shutdown, disruption or attack, it would adversely impact our product shipments and net sales, as order
processing and product distribution are heavily dependent on our management information systems. Such an interruption could also
result in a loss of our intellectual property or the release of sensitive competitive information or partner, customer or employee
personal data. Any loss of such information could harm our competitive position, result in a loss of customer confidence, and cause
us to incur significant costs to remedy the damages caused by the disruptions or security breaches. In addition, changing laws
and regulations governing our responsibility to safeguard private data could result in a significant increase in operating or capital
expenditures needed to comply with these new laws or regulations. Accordingly, our operating results in such periods would be adversely
impacted.
We are continually working to maintain
reliable systems to control costs and improve our ability to deliver our products in our markets worldwide. Our efforts include,
but are not limited to the following: firewalls, antivirus protection, patches, log monitors, routine backups with offsite retention
of storage media, system audits, data partitioning and routine password modifications. Our internal information technology systems
environment continues to evolve and our business policies and internal security controls may not keep pace as new threats emerge.
No assurance can be given that our efforts to continue to enhance our systems will be successful.
We devote significant resources to maintaining
our website, www.oxyscorp.com, as a key marketing, sales and support tool and expect to continue to do so in the future. Failure
to properly maintain our website may interrupt normal operations, including our ability to run and market our business which would
have a material adverse effect on our results of operations. We host our website internally. Any failure to successfully maintain
our website or any significant downtime or outages affecting our website could have a material adverse impact on our operating
results.
As has occurred in the past and as may
be expected to occur in the future, our new software products or new operating systems of third parties on which our products are
based often contain bugs or errors that can result in reduced sales or cause our support costs to increase, either of which could
have a material adverse impact on our operating results.
As required by Section 302 of the Sarbanes-Oxley
Act of 2002, our periodic reports contain our management’s certification of adequate disclosure controls and procedures,
a report by our management on our internal control over financial reporting including an assessment of the effectiveness of our
internal control over financial reporting, and an attestation and report by our external auditors with respect to the effectiveness
of our internal control over financial reporting under Section 404. These assessments and reports have revealed material weaknesses
in our internal control over financial reporting and compliance with Sections 302 and 404 is required for each future fiscal year
end. We expect that the ongoing compliance with Sections 302 and 404 will continue to be both very costly and very challenging
and there can be no assurance that material weaknesses will not be identified in future periods. Any adverse results from such
ongoing compliance efforts could result in a loss of investor confidence in our financial reports and have an adverse effect on
our stock price.
Our success depends on our ability to obtain
and maintain patents and other proprietary rights relative to the technologies used in our principal products. Despite our efforts
to protect our proprietary rights, unauthorized parties may have in the past infringed or violated certain of our intellectual
property rights. We from time to time may engage in litigation to protect our intellectual property rights. In monitoring and policing
our intellectual property rights, we may be required to spend significant resources. We from time to time may be notified that
we are infringing certain patent or intellectual property rights of others. There can be no assurance that any future intellectual
property dispute or litigation will not result in significant expense, liability, injunction against the sale of some of our products,
and a diversion of management’s attention, any of which may have a material adverse effect on our operating results.
Our products are designed to provide information
upon which users may rely. Our products are also used in “real time” applications requiring extremely rapid and continuous
processing and constant feedback. Such applications give rise to the risk that a failure or interruption of the system or application
could result in economic damage, bodily harm or property damage. We attempt to assure the quality and accuracy of the processes
contained in our products, and to limit our product liability exposure through contractual limitations on liability, limited warranties,
express disclaimers and warnings as well as disclaimers contained in our “shrink wrap” and electronically displayed
license agreements with end-users. If our products contain errors that produce incorrect results on which users rely or cause failure
or interruption of systems or processes, customer acceptance of our products could be adversely affected. Further, we could be
subject to liability claims that could have a material adverse effect on our operating results or financial position. Although
we maintain liability insurance for product liability matters, there can be no assurance that such insurance or the contractual
limitations used by us to limit our liability will be sufficient to cover or limit any claims which may occur.
We intend to invest a significant portion
of our efforts and financial resources in our software and we will depend heavily on its success. This software is currently in
the beta stage of development. We need to devote significant additional research and development, financial resources and personnel
to develop additional commercially viable products, establish intellectual property rights, if necessary, and establish a sales
and marketing infrastructure. We are likely to encounter hurdles and unexpected issues as we proceed in the development of our
software and our other product candidates. There are many reasons that we may not succeed in our efforts to develop our product
candidates, including the possibility that our product candidates will be deemed undesirable; our product candidates will be too
expensive to develop or market or will not achieve broad market acceptance; others will hold proprietary rights that will prevent
us from marketing our product candidates; or our competitors will market products that are perceived as equivalent or superior.
Our management includes a select group
of experienced technology professionals, particularly Clifford Emmons, Karen McNemar, and Antony Coufal, who will be instrumental
in the development of our software and product candidates. The success of our operations will, in part, depend on the successful
continued involvement of these individuals. If these individuals leave the employment of or engagement with us, OXYS, or HereLab,
then our ability to operate will be negatively impacted. We do not have any employment agreements with these parties and do not
maintain any “key-man” insurance for them.
Our common stock is trading in the over-the-counter
market and is quoted on the OTC Pink. The over-the-counter market for securities has historically experienced extreme price and
volume fluctuations during certain periods. These broad market fluctuations and other factors, such as our ability to implement
our business plan, as well as economic conditions and quarterly variations in our results of operations, may adversely affect the
market price of our common stock. In addition, the spreads on stock traded through the over-the-counter market are generally unregulated
and higher than on stock exchanges, which means that the difference between the price at which shares could be purchased by investors
on the over-the-counter market compared to the price at which they could be subsequently sold would be greater than on these exchanges.
Significant spreads between the bid and asked prices of the stock could continue during any period in which a sufficient volume
of trading is unavailable or if the stock is quoted by an insignificant number of market makers. We cannot insure that our trading
volume will be sufficient to significantly reduce this spread, or that we will have sufficient market makers to affect this spread.
These higher spreads could adversely affect investors who purchase the shares at the higher price at which the shares are sold,
but subsequently sell the shares at the lower bid prices quoted by the brokers. Unless the bid price for the stock increases and
exceeds the price paid for the shares by the investor, plus brokerage commissions or charges, shareholders could lose money on
the sale. For higher spreads such as those on over-the-counter stocks, this is likely a much greater percentage of the price of
the stock than for exchange listed stocks. There is no assurance that at the time the shareholder wishes to sell the shares, the
bid price will have sufficiently increased to create a profit on the sale.
Our shares are designated as “penny
stock” as defined in Rule 3a51-1 promulgated under the Securities Exchange Act of 1934, as amended (the “
Exchange
Act
”), and thus may be more illiquid than shares not designated as penny stock. The SEC has adopted rules which regulate
broker-dealer practices in connection with transactions in “penny stocks.” Penny stocks are defined generally as: non-Nasdaq
equity securities with a price of less than $5.00 per share; not traded on a “recognized” national exchange; or in
issuers with net tangible assets less than $2,000,000, if the issuer has been in continuous operation for at least three years,
or $10,000,000, if in continuous operation for less than three years, or with average revenues of less than $6,000,000 for the
last three years. The penny stock rules require a broker-dealer to deliver a standardized risk disclosure document prepared by
the SEC, to provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer
and its salesperson in the transaction, monthly account statements showing the market value of each penny stock held in the customer’s
account, to make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level
of trading activity, if any, in the secondary market for a stock that is subject to the penny stock rules. Since our securities
are subject to the penny stock rules, investors in the shares may find it more difficult to sell their shares. Many brokers have
decided not to trade in penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers
willing to act as market makers in such securities is limited. The reduction in the number of available market makers and other
broker-dealers willing to trade in penny stocks may limit the ability of purchasers in this offering to sell their stock in any
secondary market. These penny stock regulations, and the restrictions imposed on the resale of penny stocks by these regulations,
could adversely affect our stock price.
Under our Articles of Incorporation, our
board of directors is authorized to issue up to 10,000,000 shares of preferred stock, none of which are issued and outstanding
as of the date of this prospectus. Also, our board of directors, without shareholder approval, may determine the price, rights,
preferences, privileges and restrictions, including voting rights, of those shares. If our board of directors causes any shares
of preferred stock to be issued, the rights of the holders of our common stock could be adversely affected. Our board of directors’
ability to determine the terms of preferred stock and to cause its issuance, while providing desirable flexibility in connection
with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to
acquire a majority of our outstanding voting stock. Preferred shares issued by our board of directors could include voting rights,
or even super voting rights, which could shift the ability to control our company to the holders of our preferred stock. Preferred
shares could also have conversion rights into shares of our common stock at a discount to the market price of the common stock
which could negatively affect the market for our common stock. In addition, preferred shares would have preference in the event
of our liquidation, which means that the holders of preferred shares would be entitled to receive the net assets of our company
distributed in liquidation before the common stock holders receive any distribution of the liquidated assets.
We have not paid any cash dividends since
inception. Therefore, any return on the investment made in our shares of common stock will likely be dependent initially upon the
shareholder’s ability to sell our common shares in the open market, at prices in excess of the amount paid for our common
shares and broker commissions on the sales.
We are an “emerging growth company,”
as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and, for as long as we continue to be an “emerging
growth company,” we intend to take advantage of certain exemptions from various reporting requirements applicable to other
public companies but not to “emerging growth companies,” including, but not limited to, not being required to comply
with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an
“emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year
in which our annual gross revenues exceed $1 billion, (ii) the date that we become a “large accelerated filer” as defined
in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock that is held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which
we have issued more than $1 billion in non-convertible debt during the preceding three year period. We cannot predict if investors
will find our common stock less attractive if we choose to rely on these exemptions. If some investors find our common stock less
attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our common stock
and our stock price may be more volatile.
The statements contained in this prospectus
that are not historical facts are forward-looking statements that represent management’s beliefs and assumptions based on
currently available information. Forward-looking statements include the information concerning possible or assumed future operations,
business strategies, need for financing, competitive position, potential growth opportunities, ability to retain and recruit personnel,
the effects of competition and the effects of future legislation or regulations. Forward-looking statements include all statements
that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believes,”
“intends,” “may,” “should,” “anticipates,” “expects,” “could,”
“plans,” or comparable terminology or by discussions of strategy or trends. Although we believe that the expectations
reflected in such forward-looking statements are reasonable, we cannot give any assurances that these expectations will prove to
be correct. Such statements by their nature involve risks and uncertainties that could significantly affect expected results, and
actual future results could differ materially from those described in such forward-looking statements.
Factors that may cause differences between
actual results and those contemplated by forward-looking statements include those discussed in “Risk Factors” and are
not limited to the following:
Should one or more of these risks materialize
(or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could
differ materially from those expected. We disclaim any intention or obligation to update publicly or revise such statements whether
as a result of new information, future events or otherwise.
There may also be other risks and uncertainties
that we are unable to identify and/or predict at this time or that we do not now expect to have a material adverse impact on our
business.
We will not receive any proceeds from the sale of the common
stock by the selling stockholders.
Our common stock is quoted on the OTC Pink
under the symbol “ITOX.” The table below sets forth for the periods indicated the quarterly high and low bid prices
as reported by OTC Markets. Limited trading volume has occurred during these periods. These quotations reflect inter-dealer prices,
without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions.
Our common stock is considered to be penny
stock under rules promulgated by the Securities and Exchange Commission (the “
SEC
”). Under these rules, broker-dealers
participating in transactions in these securities must first deliver a risk disclosure document which describes risks associated
with these stocks, broker-dealers’ duties, customers’ rights and remedies, market and other information, and make suitability
determinations approving the customers for these stock transactions based on financial situation, investment experience and objectives.
Broker-dealers must also disclose these restrictions in writing, provide monthly account statements to customers, and obtain specific
written consent of each customer. With these restrictions, the likely effect of designation as a penny stock is to decrease the
willingness of broker-dealers to make a market for the stock, to decrease the liquidity of the stock and increase the transaction
cost of sales and purchases of these stocks compared to other securities.
We were a shell company prior to the filing
of our report on Form 8-K on August 3, 2017. Rule 144 is not available for the resale of securities issued by companies that are,
or previously were, shell companies, such as our company, unless certain conditions are met. Paragraph (i) of Rule 144 prohibits
the use of the rule for resale of securities issued by any shell companies (other than business combination related shell companies)
or any issuer that has been at any time previously a shell company, except where the following conditions are met:
As a result, our shareholders will not
be able to sell their shares of our common stock under Rule 144 at least prior to the one-year anniversary of the filing of our
Current Report on Form 8-K on August 3, 2017.
As of the close of business on April 16,
2019, we had approximately 133 holders of our common stock. The number of record holders was determined from the records of our
transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers,
dealers, and registered clearing agencies. We have appointed Issuer Direct, 1981 East 4800 South, Suite 100, Salt Lake City, UT
84117, to act as transfer agent for the common stock.
We have not declared or paid any cash dividends
on our common stock during the fiscal years ended December 31, 2018 and 2017, or in any subsequent period. We do not anticipate
or contemplate paying dividends on our common stock at the present time. The only restrictions that limit the ability to pay dividends
on common equity, or that are likely to do so in the future, are those restrictions imposed by law.
Securities Authorized for Issuance
under Equity Compensation Plans
Equity
Compensation Plan Information
Plan category
|
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights
|
|
|
Weighted-average exercise price of outstanding options, warrants and rights
|
|
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
|
|
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
Equity compensation plans approved by security holders
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
Equity compensation plans not approved by security holders
|
|
|
384,615
|
|
|
$
|
0.75
|
|
|
|
91,000
|
(1)(2)(3)
|
Total
|
|
|
384,615
|
|
|
$
|
0.75
|
|
|
|
91,000
|
|
|
(1)
|
Effective July 1, 2018, the Company issued to Sam Burke 200,000 unvested shares of the Company’s Common Stock under the 2017 Plan, as defined below.
|
|
(2)
|
Effective April 23, 2018, the Company issued to Antony Coufal 1,800,000 unvested shares of the Company’s Common Stock under the 2017 Plan, as defined below.
|
|
(3)
|
Effective October 1, 2018, the Company issued to Karen McNemar 2,409,000 unvested shares of the Company’s Common Stock under the 2017 Plan, as defined below.
|
2017 Stock Incentive Plan
On March 16, 2017, our board of directors
assumed the 2017 Stock Awards Plan adopted by the Company while domiciled in New Jersey. No awards were made under this plan. On
December 14, 2017, the Board of Directors terminated this plan and adopted a new 2017 Stock Incentive Plan (the “
2017
Plan
”). The purposes of the 2017 Plan are (a) to enhance our ability to attract and retain the services of qualified
employees, officers, directors, consultants, and other service providers upon whose judgment, initiative and efforts the successful
conduct and development of our business largely depends, and (b) to provide additional incentives to such persons or entities to
devote their utmost effort and skill to the advancement and betterment of our company, by providing them an opportunity to participate
in the ownership of our Company and thereby have an interest in the success and increased value of our Company.
There are 4,500,000 shares of common stock
authorized for non-qualified and incentive stock options, restricted stock units, restricted stock grants, and stock appreciation
rights under the 2017 Plan, which are subject to adjustment in the event of stock splits, stock dividends, and other situations.
The 2017 Plan is administered by our board
of directors; however, the board of directors may designate administration of the 2017 Plan to a committee consisting of at least
two independent directors. Only employees of our Company or of an “Affiliated Company”, as defined in the 2017 Plan,
(including members of the board of directors if they are employees of our Company or of an Affiliated Company) are eligible to
receive incentive stock options under the Plan. Employees of our Company or of an Affiliated Company, members of the board of directors
(whether or not employed by our company or an Affiliated Company), and “Service Providers”, as defined in the 2017
Plan, are eligible to receive non-qualified options, restricted stock units, and stock appreciation rights under the 2017 Plan.
All awards are subject to Section 162(m) of the Internal Revenue Code.
No option awards may be exercisable more
than ten years after the date it is granted. In the event of termination of employment for cause, the options terminate on the
date of employment is terminated. In the event of termination of employment for disability or death, the optionee or administrator
of optionee’s estate or transferee has six months following the date of termination to exercise options received at the time
of disability or death. In the event of termination for any other reason other than for cause, disability or death, the optionee
has 30 days to exercise his or her options.
The 2017 Plan will continue in effect until
all the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until ten years
after its adoption, whichever is earlier. Awards under the 2017 Plan may also be accelerated in the event of certain corporate
transactions such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all our assets.
As of December 31, 2018, the Board had
granted 4,409,000 shares of unvested shares of Common Stock under the 2017 Plan.
2019 Stock Incentive Plan
On March 11, 2019, the Board of Directors
adopted the 2019 Stock Incentive Plan (the “
2019 Plan
”). The purposes of the 2019 Plan are (a) to enhance our
ability to attract and retain the services of qualified employees, officers, directors, consultants, and other service providers
upon whose judgment, initiative and efforts the successful conduct and development of our business largely depends, and (b) to
provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment
of our company, by providing them an opportunity to participate in the ownership of our Company and thereby have an interest in
the success and increased value of our Company.
The 2019 Plan is administered by our board
of directors; however, the board of directors may designate administration of the 2019 Plan to a committee consisting of at least
two independent directors. Only employees of our Company or of an “Affiliated Company”, as defined in the 2019 Plan,
(including members of the board of directors if they are employees of our Company or of an Affiliated Company) are eligible to
receive incentive stock options under the 2019 Plan. Employees of our Company or of an Affiliated Company, members of the board
of directors (whether or not employed by our company or an Affiliated Company), and “Service Providers”, as defined
in the 2019 Plan, are eligible to receive non-qualified options, restricted stock units, and stock appreciation rights under the
2019 Plan. All awards are subject to Section 162(m) of the Internal Revenue Code.
No option awards may be exercisable more
than ten years after the date it is granted. In the event of termination of employment for cause, the options terminate on the
date of employment is terminated. In the event of termination of employment for disability or death, the optionee or administrator
of optionee’s estate or transferee has six months following the date of termination to exercise options received at the time
of disability or death. In the event of termination for any other reason other than for cause, disability or death, the optionee
has 30 days to exercise his or her options.
The 2019 Plan will continue in effect until
all the stock available for grant or issuance has been acquired through exercise of options or grants of shares, or until ten years
after its adoption, whichever is earlier. Awards under the 2019 Plan may also be accelerated in the event of certain corporate
transactions such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all our assets.
MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management’s Discussion and
Analysis of Financial Condition and Results of Operations contain certain forward-looking statements. Historical results may not
indicate future performance. Our forward-looking statements reflect our current views about future events; are based on assumptions
and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated
by these statements. Factors that may cause differences between actual results and those contemplated by forward-looking statements
include, but are not limited to, those discussed above and in “Risk Factors.” We undertake no obligation to publicly
update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances
after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels
of activity, performance, or achievements
Basis of Presentation
The financial information presented below
and the following Management Discussion and Analysis of the Consolidated Financial Condition, Results of Operations, Stockholders’
Equity and Cash Flow for the periods ended December 31, 2017 and 2018 gives effect to our acquisition of OXYS Corporation (“
OXYS
”)
on July 28, 2017. In accordance with the accounting reporting requirements for the recapitalization related to the “reverse
merger” of OXYS, the financial statements for OXYS have been adjusted to reflect the change in the shares outstanding and
the par value of the common stock of OXYS. Additionally, all intercompany transactions between the Company and OXYS have been eliminated.
Forward-Looking Statements
Statements in this management’s discussion
and analysis of financial condition and results of operations contain certain forward-looking statements. To the extent that such
statements are not recitations of historical fact, such statements constitute forward looking statements which, by definition involve
risks and uncertainties. Where in any forward-looking statements, if we express an expectation or belief as to future results or
events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance
that the statement of expectation or belief will result or be achieved or accomplished.
Factors that may cause differences between
actual results and those contemplated by forward-looking statements include those discussed in “Risk Factors” and are
not limited to the following:
|
·
|
general market and economic conditions;
|
|
·
|
our ability to maintain and grow our business with our current customers;
|
|
·
|
our ability to meet the volume and service requirements of our customers;
|
|
·
|
industry consolidation, including acquisitions by us or our competitors;
|
|
·
|
capacity utilization and the efficiency of manufacturing operations;
|
|
·
|
success in developing new products;
|
|
·
|
timing of our new product introductions;
|
|
·
|
new product introductions by competitors;
|
|
·
|
the ability of competitors to more fully leverage low cost geographies for manufacturing or distribution;
|
|
·
|
product pricing, including the impact of currency exchange rates;
|
|
·
|
effectiveness of sales and marketing resources and strategies;
|
|
·
|
adequate manufacturing capacity and supply of components and materials;
|
|
·
|
strategic relationships with our suppliers;
|
|
·
|
product quality and performance;
|
|
·
|
protection of our products by effective use of intellectual property laws;
|
|
·
|
the financial strength of our competitors;
|
|
·
|
the outcome of any future litigation or commercial dispute;
|
|
·
|
barriers to entry imposed by competitors with significant market power in new markets;
|
|
·
|
government actions throughout the world; and
|
|
·
|
our ability to service secured debt, when due.
|
You should not rely on forward-looking
statements in this document. This management’s discussion contains forward looking statements that involve risks and uncertainties.
We use words such as “anticipates,” “believes,” “plans,” “expects,” “future,”
“intends,” and similar expressions to identify these forward-looking statements. Prospective investors should not place
undue reliance on these statements, which apply only as of the date of this document. Our actual results could differ materially
from those anticipated in these forward-looking statements.
Critical Accounting Policies
The following discussions are based upon
our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.
These financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted
in the United States.
The preparation of these financial statements
requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosures of contingencies. We continually evaluate the accounting policies and estimates used to prepare
the financial statements. We base our estimates on historical experiences and assumptions believed to be reasonable under current
facts and circumstances. Actual amounts and results could differ from these estimates made by management.
Trends and Uncertainties
On July 28, 2017, we closed the reverse
acquisition transaction under the Securities Exchange Agreement dated March 16, 2017, as reported in the Company’s report
on Form 8-K filed with the Commission on August 3, 2017. Following the closing, the business of the Company has been that of OXYS,
Inc. and HereLab, Inc., our wholly owned subsidiaries. The operations of the Company have varied significantly following the closing
since prior to that time, the Company was an inactive shell company.
Historical Background
We were incorporated in the State of New
Jersey on October 1, 2003 under the name of Creative Beauty Supply of New Jersey Corporation and subsequently changed our name
to Gotham Capital Holdings, Inc. on May 18, 2015. We commenced operations in the beauty supply industry as of January 1, 2004.
On November 30, 2007, our Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. From
January 1, 2009 until July 28, 2017, we had no operations and were a shell company.
On March 16, 2017, our Board of Directors
adopted resolutions, which were approved by shareholders holding a majority of our outstanding shares, to change our name to “IIOT-OXYS,
Inc.”, to authorize a change of domicile from New Jersey to Nevada, to authorize a 2017 Stock Awards Plan, and to approve
the Securities Exchange Agreement (the “
OXYS SEA
”) between the Company and OXYS Corporation (“
OXYS
”),
a Nevada corporation incorporated on August 4, 2016.
Under the terms of the OXYS SEA we acquired
100% of the issued voting shares of OXYS in exchange for 34,687,244 shares of our Common Stock. We also cancelled 1,500,000 outstanding
shares of our Common Stock and changed our management to Mr. DiBiase who also served in management of OXYS. Also, one of our principal
shareholders entered into a consulting agreement with OXYS to provide consulting services during the transition. The OXYS SEA was
effective on July 28, 2017, and our name was changed to “IIOT-OXYS, Inc.” at that time. Effective October 26, 2017,
our domicile was changed from New Jersey to Nevada.
On December 14, 2017, we entered into a
Share Exchange Agreement (the “
HereLab SEA
”) with HereLab, Inc., a Delaware corporation (“
HereLab
”),
and HereLab’s two shareholders pursuant to which we would acquire all the issued and outstanding shares of HereLab in exchange
for the issuance of 1,650,000 shares of our Common Stock, on a pro rata basis, to HereLab’s two shareholders. The closing
of the transaction occurred on January 11, 2018 and HereLab became our wholly-owned subsidiary.
At the present time, we have two, wholly-owned
subsidiaries which are OXYS Corporation and HereLab, Inc., through which our operations are conducted.
General Overview
IIOT-OXYS, Inc., a Nevada corporation
(the “
Company
”), and OXYS, were originally established for the purposes of designing, building, testing,
and selling Edge Computing systems for the Industrial Internet.
Both companies were, and presently are, early stage
technology startups that are largely pre-revenue in their development phase.
HereLab is also an early-stage
technology development company. The Company received its first revenues in the last quarter of 2017, continued to realize
revenues during 2018, and expects to realize revenue growth in 2019 due to its business development pipeline.
We develop hardware,
software and algorithms that monitor, measure and predict conditions for energy, structural, agricultural and medical applications.
We use domain-specific Artificial Intelligence to solve industrial and environmental challenges. Our engineered solutions focus
on common sense approaches to machine learning, algorithm development and hardware and software products.
Our customers
have issues and they need improvements. We design a system of hardware and software, assemble, install, monitor data and
apply our algorithms to help provide the customer insights.
We use off the
shelf components, with reconfigurable hardware architecture that adapts to a wide range of customer needs and applications.
We use open source software tools, while still creating proprietary content for customers, thereby reducing software development
time and cost. The software works with the hardware to collect data from the equipment or structure that is being monitored.
We focus on developing
insights. We develop algorithms that help our customers create insights from vast data streams. The data collected
is analyzed and reports are created for the customer. From these insights, the customer can act to improve their process,
product or structure.
OUR SOLUTIONS ACHIEVE TWO OBJECTIVES
ADD VALUE
|
·
|
We show clear path to improved asset reliability, machine uptime, machine utilization, energy consumption, and quality.
|
|
·
|
We provide advanced algorithms and insights as a service.
|
RISK MINIMIZATION
|
·
|
We use simple measurements requiring almost zero integration – minimally invasive.
|
|
·
|
We do not interfere with command and control of critical equipment.
|
|
·
|
We do not physically touch machine control networks – total isolation of networks.
|
HOW WE DO IT
Our location in Cambridge, Massachusetts
is ideal since market-leading Biotech, Medtech, and Pharma multinational firms have offices or R&D centers in Cambridge or
the Greater Boston area, which gives us easier access to potential sales which, in turn, lowers out cost of sales. Additionally,
we continue to add value to structural health monitoring and smart manufacturing customers as well. We, therefore, have a range
of opportunities as we continue to expand our customer base.
Our goal is to help Biotech, Pharma, and
Medical Device companies realize the next wave of performance, productivity, and quality gains for their organizations, and become
Industry 4.0 compliant.
We have a unique value proposition in a
fast-growing worldwide multi-billion USD market, and have positioned our business with strategic partners for accelerated growth.
We are therefore well-poised for rapid growth in 2019 and beyond, as we execute our plans and quickly acquire additional customers.
WHAT MARKETS WE SERVE
SMART MANUFACTURING
We help our customers maintain machine
uptime and maximize operational efficiency. We also enable then to do energy monitoring, predictive maintenance that anticipates
problems before they happen, and improve part and process quality.
BIOTECH, PHARMACEUTICAL, AND MEDICAL
DEVICES
We are on the operations side, not the
patient-facing side. In this market vertical, our customers must provide high-quality products that must also pass rigorous review
by governing bodies such as the FDA. Here again, we focus on machine uptime, operational efficiency, and predictive maintenance
to avoid unplanned downtime.
SMART INFRASTRUCTURE
For bridges and other civil infrastructure,
local, state and federal agencies have limited resources. We help our clients prioritize how to spend limited funds by addressing
those fixes which need to be made first.
OUR UNIQUE VALUE PROPOSITION
EDGE COMPUTING AS A COMPLIMENT TO CLOUD
COMPUTING
Within the Internet of Things (“
IoT
”)
and Industrial Internet of Things (“
IIoT
”), most companies right now are adopting an approach which sends all
sensor data to the cloud for processing. We specialize in edge computing, where the data processing is done locally right where
the data is collected. We also have advanced cloud-based algorithms that implement various machine learning and artificial intelligence
algorithms.
ADVANCED ALGORITHMS
We have sought to differentiate from our
competitors by developing advanced algorithms on our own and in collaboration with world-leading research institutions. These algorithms
are an essential part of the edge computing strategy that convert raw data into actionable knowledge right where the data is collected
without having to send the data to the cloud first.
RECONFIGURABLE HARDWARE AND SOFTWARE
Instead of focusing on creating tools,
we use open source tools to create proprietary content.
Liquidity and Capital Resources for
the Year Ended December 31, 2018 Compared to the Year Ended December 31, 2017
At December 31, 2018, the Company had a
cash balance of $39,226, which represents a $21,637 decrease from the $60,863 balance at December 31, 2017. This decrease was primarily
the result of cash used to satisfy the requirements of a reporting company and due to acceleration in product development activities.
The Company’s working capital at December 31, 2018 was negative $751,696, as compared to a December 31, 2017 working capital
of $77,663.
For the year ended December 31, 2018, we
incurred a net loss of $1,613,299. Net cash used in operating activities was $521,637 for the year ended December 31, 2018.
For the year ended December 31, 2017, we
incurred a net loss of $1,531,095. Net cash used in operating activities was $490,701 for the year ended December 31, 2017.
For the year ended December 31, 2018, investing
activities consisted of $0. During the same period, financing activities consisted of $500,000 of cash received from the issuance
of a Convertible Note.
For the year ended December 31, 2017, investing
activities consisted of $1,000 of cash paid in conjunction with a licensing agreement. During the same period, financing activities
consisted of cash received totaling $70,723 from issuance of common stock net of costs.
The accompanying financial statements have
been prepared assuming the Company will continue as a going concern. As shown in the accompanying financial statements, the Company
has incurred losses from operations of $1,613,299 for the year ended December 31, 2018, and $1,531,095 for the year ended December
31, 2017 and has an accumulated deficiency which raises substantial doubt about the Company’s ability to continue as a going
concern.
Results of Operations for the Year
Ended December 31, 2018 compared to the year ended December 31, 2017
For the year ended December 31, 2018, we
earned revenues of $224,643 and incurred related cost of sales of $135,008. We incurred professional fees of $1,152,798 and other
general and administrative expenses of $259,592. We incurred other expenses net of income of $290,544. As a result, we incurred
a net loss of $1,613,299 for the year ended December 31, 2018.
Comparatively, for the year ended December
31, 2017, we earned revenues of $39,800 and incurred related cost of sales of $47,887. We incurred professional fees of $1,416,527
and other general and administrative expenses of $106,469. We incurred other expenses of $12. As a result, we incurred a net loss
of $1,531,095 for the year ended December 31, 2017.
During the current and prior period, the
Company did not record an income tax benefit due to the uncertainty associated with the Company’s ability to utilize the
deferred tax assets.
Year over Year (YoY) revenue growth in
2018 was more than 5x. This significant achievement is attributed to several factors: the installation of an experienced leadership
team; expansion of our technology team, especially in the area of Artificial Intelligence & Machine Learning (AI & ML);
execution of contracts secured; and focus on high potential growth markets (specifically Biotech, Pharma, and Medical Device Operations).
Furthermore, this impressive YoY revenue growth is a confirmation of the rapid growth of the Industrial Internet of Things (IIoT)
market, and our unique value proposition to serve said rapidly growing market. Market research shows the worldwide IIoT market
in 2017 was $92 billion and is projected to be $227 billion by 2021 (25% CAGR).
1
Our edge computing open-source
hardware and proprietary ML algorithms employ our Minimally-Invasive Load Monitoring (MILM) technology to simply gather data and
gain insights to monitor and scope power, move from preventive to predictive maintenance, and even optimize development and manufacturing
processes. This unique value proposition has been embraced by our customers, including a Fortune 500 Pharmaceutical Manufacturer.
It is important to note that this rapid YoY revenue came about despite capital funding lagging behind previously anticipated levels.
It is anticipated that 2019 YoY revenue
growth will meet or exceed that of 2018. This is due to the factors stated above that are now firmly in place: experienced leadership;
savvy technological talent, operational execution excellence; and focus on new customers and expanded business with the current
customer base. Combined with the continued robust growth of the IIoT market and the infusion of additional capital funding (note:
$155,000 was raised in Q1 2019), we believe we are poised for strong growth and performance in 2019.
Recently Issued Accounting Standards
Management does not believe that any other
recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying
financial statements.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.
Emerging Growth Company
We are an “emerging growth company,”
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Certain specified reduced reporting and other regulatory
requirements that are available to public companies that are emerging growth companies. These provisions include:
|
1.
|
an exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002;
|
|
2.
|
an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies;
|
|
3.
|
an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about our audit and our financial statements; and
|
|
4.
|
reduced disclosure about our executive compensation arrangements.
|
We have elected to take advantage of the
exemption from the adoption of new or revised financial accounting standards until they would apply to private companies. As a
result of this election, our financial statements may not be comparable to public companies required to adopt these new requirements.
_______________
1
https://www.ptc.com/-/media/Files/PDFs/IoT/State-of-IIoT-Whitepaper.pdf
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
On January 16, 2018,
Pritchett
Siler & Hardy, P.C.
(“
Pritchett Siler & Hardy
”), resigned as principal accountant of IIOT-OXYS,
Inc., a Nevada corporation (the “
Company
”) due to an acquisition of Pritchett Siler & Hardy by Haynie &
Company, Salt Lake City, Utah (“
Haynie
”). On January 16, 2018 the Company engaged
Haynie
as
the Company’s principal accountant for the Company’s fiscal year ended December 31, 2017. The decision to appoint Haynie
as the Company’s principal accountant was approved by the Company’s Board of Directors.
Due to the fact that Pritchett Siler &
Hardy was appointed as the Company’s principal accountant on August 8, 2017, Pritchett Siler & Hardy did not issue any
reports on the Company’s financial statements for either of the past two years.
There were no disagreements between the
Company and Pritchett Siler & Hardy, for the two most recent fiscal years and any subsequent interim period through January
16, 2018 (date of resignation) on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which, if not resolved to the satisfaction of Pritchett Siler & Hardy, would have caused them to make reference
to the subject matter of the disagreement in connection with its report. Further, Pritchett Siler & Hardy has not advised the
Company that:
|
1)
|
internal controls necessary to develop reliable financial statements did not exist; or
|
|
2)
|
information has come to the attention of Pritchett Siler & Hardy which made it unwilling to rely upon management’s representations, or made it unwilling to be associated with the financial statements prepared by management; or
|
|
3)
|
the scope of the audit should be expanded significantly, or information has come to the attention of Pritchett Siler & Hardy that they have concluded will, or if further investigated, might materially impact the fairness or reliability of a previously issued audit report or the underlying financial statements, or the financial statements issued or to be issued covering the fiscal year ended December 31, 2017.
|
On January 16, 2018, the Company engaged
Haynie as its principal accountant to audit the Company’s financial statements as successor to Pritchett Siler & Hardy.
During the Company’s two most recent fiscal years or subsequent interim period, the Company has not consulted with Haynie
regarding the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit
opinion that might be rendered on the Company’s financial statements, nor did Haynie provide advice to the Company, either
written or oral, that was an important factor considered by the Company in reaching a decision as to the accounting, auditing or
financial reporting issue.
Further, during the Company’s two
most recent fiscal years or subsequent interim period, the Company has not consulted Haynie on any matter that was the subject
of a disagreement or a reportable event.
BUSINESS AND PROPERTIES
Historical Background
We were incorporated in the State of New
Jersey on October 1, 2003 under the name of Creative Beauty Supply of New Jersey Corporation and subsequently changed our name
to Gotham Capital Holdings, Inc. on May 18, 2015. We commenced operations in the beauty supply industry as of January 1, 2004.
On November 30, 2007, our Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. From
January 1, 2009 until July 28, 2017, we had no operations and were a shell company.
On March 16, 2017, our Board of Directors
adopted resolutions, which were approved by shareholders holding a majority of our outstanding shares, to change our name to “IIOT-OXYS,
Inc.”, to authorize a change of domicile from New Jersey to Nevada, to authorize a 2017 Stock Awards Plan, and to approve
the Securities Exchange Agreement (the “
OXYS SEA
”) between the Company and OXYS Corporation (“
OXYS
”),
a Nevada corporation incorporated on August 4, 2016.
Under the terms of the OXYS SEA we acquired
100% of our issued voting shares of OXYS in exchange for 34,687,244 shares of our Common Stock. We also cancelled 1,500,000 outstanding
shares of our Common Stock and changed our management to Mr. DiBiase who also served in management of OXYS. Also, one of our principal
shareholders entered into a consulting agreement with OXYS to provide consulting services during the transition. The OXYS SEA was
effective on July 28, 2017, and our name was changed to “IIOT-OXYS, Inc.” at that time. Effective October 26, 2017,
our domicile was changed from New Jersey to Nevada.
On December 14, 2017, we entered into a
Share Exchange Agreement (the “
HereLab SEA
”) with HereLab, Inc., a Delaware corporation (“
HereLab
”),
and HereLab’s two shareholders pursuant to which we would acquire all the issued and outstanding shares of HereLab in exchange
for the issuance of 1,650,000 shares of our Common Stock, on a pro rata basis, to HereLab’s two shareholders. The closing
of the transaction occurred on January 11, 2018 and HereLab became our wholly-owned subsidiary.
At the present time, we have two, wholly-owned
subsidiaries which are OXYS Corporation and HereLab, Inc., through which our operations are conducted.
General Overview
IIOT-OXYS, Inc., a Nevada corporation (the
“
Company
”), and OXYS, were originally established for the purposes of designing, building, testing, and selling
Edge Computing systems for the Industrial Internet.
Both companies were, and presently are, early stage technology startups
that are largely pre-revenue in their development phase.
HereLab is also an early-stage technology development company.
The Company received its first revenues in the last quarter of 2017, continued to realize revenues during 2018, and expects to
realize revenue growth in 2019 due to its business development pipeline.
We develop hardware,
software and algorithms that monitor, measure and predict conditions for energy, structural, agricultural and medical applications.
We use domain-specific Artificial Intelligence to solve industrial and environmental challenges. Our engineered solutions focus
on common sense approaches to machine learning, algorithm development and hardware and software products.
Our customers
have issues and they need improvements. We design a system of hardware and software, assemble, install, monitor data and
apply our algorithms to help provide the customer insights.
We use off the
shelf components, with reconfigurable hardware architecture that adapts to a wide range of customer needs and applications.
We use open source software tools, while still creating proprietary content for customers, thereby reducing software development
time and cost. The software works with the hardware to collect data from the equipment or structure that is being monitored.
We focus on developing
insights. We develop algorithms that help our customers create insights from vast data streams. The data collected
is analyzed and reports are created for the customer. From these insights, the customer can act to improve their process,
product or structure.
OUR SOLUTIONS ACHIEVE TWO OBJECTIVES
ADD VALUE
|
·
|
We show clear path to improved asset reliability, machine uptime, machine utilization, energy consumption, and quality.
|
|
·
|
We provide advanced algorithms and insights as a service.
|
RISK MINIMIZATION
|
·
|
We use simple measurements requiring almost zero integration – minimally invasive.
|
|
·
|
We do not interfere with command and control of critical equipment.
|
|
·
|
We do not physically touch machine control networks – total isolation of networks.
|
HOW WE DO IT
Our location in Cambridge, Massachusetts
is ideal since market-leading Biotech, Medtech, and Pharma multinational firms have offices or R&D centers in Cambridge or
the Greater Boston area, which gives us easier access to potential sales which, in turn, lowers out cost of sales. Additionally,
we continue to add value to structural health monitoring and smart manufacturing customers as well. We, therefore, have a range
of opportunities as we continue to expand our customer base.
Our goal is to help Biotech, Pharma, and
Medical Device companies realize the next wave of performance, productivity, and quality gains for their organizations, and become
Industry 4.0 compliant.
We have a unique value proposition in a
fast-growing worldwide multi-billion USD market, and have positioned with strategic partners for accelerated growth. We are therefore
well-poised for rapid growth in 2019 and beyond, as we execute our plans and quickly acquire additional customers.
WHAT MARKETS WE SERVE
SMART MANUFACTURING
We help our customers maintain machine
uptime and maximize operational efficiency. We also enable then to do energy monitoring, predictive maintenance that anticipates
problems before they happen, and improve part and process quality.
BIOTECH, PHARMACEUTICAL, AND MEDICAL
DEVICES
We are on the operations side, not the
patient-facing side. In this market vertical, our customers must provide high-quality products that must also pass rigorous review
by governing bodies such as the FDA. Here again, we focus on machine uptime, operational efficiency, and predictive maintenance
to avoid unplanned downtime.
SMART INFRASTRUCTURE
For bridges and other civil infrastructure,
local, state and federal agencies have limited resources. We help our clients prioritize how to spend limited funds by addressing
those fixes which need to be made first.
OUR UNIQUE VALUE PROPOSITION
EDGE COMPUTING AS A COMPLIMENT TO CLOUD
COMPUTING
Within the Internet of Things (“
IoT
”)
and Industrial Internet of Things (“
IIoT
”), most companies right now are adopting an approach which sends all
sensor data to the cloud for processing. We specialize in edge computing, where the data processing is done locally right where
the data is collected. We also have advanced cloud-based algorithms that implement various machine learning and artificial intelligence
algorithms.
ADVANCED ALGORITHMS
We have sought to differentiate from our
competitors by developing advanced algorithms on our own and in collaboration with world-leading research institutions. These algorithms
are an essential part of the edge computing strategy that convert raw data into actionable knowledge right where the data is collected
without having to send the data to the cloud first.
RECONFIGURABLE HARDWARE AND SOFTWARE
Instead of focusing on creating tools,
we use open source tools to create proprietary content.
SIGNIFICANT ACCOMPLISHMENTS IN 2018
A new management team was put into place
in 2018. After the new team took over, the following significant accomplishments were achieved:
|
·
|
June 2018 --- Clifford Emmons appointed as CEO and interim CFO bringing decades of operational expertise in med device and a proven track record of revenue generation;
|
|
·
|
July 2018 --- machine learning engineer and other technical personnel added to our team;
|
|
·
|
August 2018 --- delivery of system to automotive customer;
|
|
·
|
September 2018 --- S-1 Registration Statement declared effective;
|
|
·
|
September 2018 --- appointment of Karen McNemar as our COO bringing significant operational experience from the medical device industry
|
|
·
|
October 2018 --- application of our technology to 3D printing of metal components;
|
|
·
|
October 2018 --- Master Service Agreement signed with key pharmaceutical customer;
|
|
·
|
October 2018 --- installation of equipment for automotive customer complete;
|
|
·
|
November 2018 --- additional work scope awarded on structural health monitoring system to enable remote operations off grid;
|
|
·
|
November 2018 --- additional work at automotive supplier leads to request for proposal to expand services into data analytics;
|
|
·
|
November 2018 --- successful delivery of first phase of work for large pharmaceutical client and work successfully executed onsite in Asia;
|
|
·
|
November 2018 --- joined the Industrial Internet Consortium, the premier International Industry Organization that is shaping the future course of the Industrial Internet;
|
|
·
|
November 2018 --- attended IIC Quarterly Meeting in Beijing, China and initiated discussions with strategic partner in Asia;
|
|
·
|
December 2018 --- asked to submit a second phase of proposed work under the Master Service Agreement with large pharmaceutical customer; and
|
|
·
|
December 2018 --- entered into discussions with three potential Biotech and Pharma customers with initial discussions on proposed activities underway.
|
As can be seen, we are making rapid progress
towards our stated goal of becoming a leading supplier of Edge Computing, Machine Learning, and Algorithmic Insights.
SHARPENING THE 2019 FOCUS
In addition to the work we continue to
do for structural health monitoring and industrial applications, we are committed to expanding our offerings and customer base
in Biotech, Medtech, and Pharma. Our goal is to help Biotech, Pharma, and Medical Device companies' operations leaders realize
the next wave of productivity & quality assurance gains for their organizations and become Industry 4.0 compliant
2
.
Our edge computing open-source hardware and proprietary ML algorithms employ our Minimally-Invasive Load Monitoring (MILM) technology
3
to
simply gather data and gain insights to monitor, scope, move from preventive to predictive maintenance, and even optimize development
and manufacturing processes. We have a unique value proposition in a fast-growing worldwide multi-billion USD market, and have
positioned ourselves with strategic partners for accelerated growth. We have already proven our ability to add value by signing
agreements with major firms in this space, with the next three expected soon, and targeting our first ten by the end of 2019. Therefore,
we have begun our next great phase of growth as a company to serve these needs at the intersection of Artificial Intelligence,
Machine Learning, and Healthcare Operations and Production.
GAINING MOMENTUM ON THE FINANCIAL FRONT
We expect the first half of 2019 to be
better in terms of revenue growth than the last half of 2018, and significant new contracts are expected in 2019 within our target
market segments of Biotech, Pharma, and Medtech. We continue to expand our efforts in Industrial and structural health monitoring
applications as well, thereby providing a diverse and well-balanced customer base but with significant focus areas as well. Overall,
we expect 2019 year on year revenue to increase by a greater factor than 2018 year on year revenue, and we are committed to continuing
this geometric progression of revenue growth into the future as we rapidly expand.
We are also pleased to announce that we
have secured an interim funding in the amount of $55,000 from the CEO and two other founders, through Cambridge MedSpace LLC, a
medical industry focused incubator located in Cambridge with deep connections to the Biotech, Pharma, and Medtech markets and investor
networks. We will continue fundraising activities in 2019 that will enable the addition of increased technical and sales staff
for expanded revenue growth and to increase our customer base.
TOWARDS A SUCCESSFUL 2019 AND BEYOND
We are poised for strong growth and performance
in 2019. We are setting our sights on adding our next three customers, on our way to our first ten Biotech, Pharma & MedTech
customers by year end, accelerating our business development efforts, starting and sustaining operations in Asia, and of course
additional future fund raising activities to fuel and propel this significant growth. We are taking an aggressive approach of nurturing
strong organic growth, identifying opportunities for growth through acquisition, and other joint ventures or mergers that could
make sense for our business and add value for our shareholders. Some of the specific 2019 markets and opportunities we are pursuing
include, but are not limited to:
|
·
|
A large aerospace client;
|
|
·
|
Up to ten additional customers in the Biotech, Medtech, and Pharma space;
|
|
·
|
Expanding our deployments in the monitoring of civil infrastructure; and
|
|
·
|
Expanding our deployments in the smart manufacturing arena for automotive.
|
Marketing
Our marketing and sales efforts are divided
into several distinct categories:
|
1)
|
Working with technical partners who have larger sales forces;
|
|
2)
|
Direct business development and discussions with end use customers by company management;
|
_______________
2
Industry
4.0 is a name given to the current trend of automation and data exchange in manufacturing technologies. It includes cyber-physical
systems, the Internet of things, cloud computing and cognitive computing. Industry 4.0 is commonly referred to as the fourth industrial
revolution.
3
Minimally Invasive Load Monitoring (MILM) refers to the method and technique of using purely
electrical signals to make inferences on the state of a machine tool, process, and some other physical system. The underlying
premise is that electro-mechanical systems, or cyber-physical systems, or electro-chemical systems, or any system that uses electrical
power as its primary motive power, will have a linkage between physical states of the machine or the process and electrical transient
or "signatures" which will be measurable on the electrical power lines which provide energy to aforementioned systems.
Therefore, by measuring, analyzing, understanding, and classifying these electrical transient, it is possible to make inferences
on the state of the associated machine or process which is powered by those electrical line. This allows for a very simple,
minimally-invasive monitoring system that can be very useful in an industrial or production setting, or for many other applications
that could benefit from such monitoring.
|
3)
|
Working with distribution channel partners who can leverage their existing sales channels for increased visibility; and
|
|
4)
|
Trade shows and international technical, sales and marketing meetings.
|
Although the present expenditures on marketing
and sales have been modest (less than 10% of expenditures) they are expected to increase in 2019 and we expect to hire a business
development manager after the next funding to coordinate and focus our marketing and sales efforts.
Competition
We have two principal sources of competition.
The first comes from large companies such as IBM, GE, Amazon, Google, etc., who all have their efforts in IIoT. However, these
large companies are cloud – computing centric and they are trying to move towards edge devices from their present position
of being solely cloud computing based. We will be starting in edge computing from day one as opposed to force-fitting a cloud-based
solution into the limited computational capability and storage space of an edge device. We believe our systems will be more computationally
efficient as compared to a cloud-based solution which requires more computational resources. We also believe our systems will embody
unique algorithms such as those we previously licensed and seek to license from such research institutions as the National Labs.
Most of the IIoT implementations involve
data going from sensor to cloud. This involves sending vast amounts of data to the cloud and then processing the data there. This
requires a large computational footprint (many processors) and a large memory requirement to store the data. From our actual experience
and according to many technical experts in the field (see for example the discussion on edge data in “Structural Health Monitoring”
A Machine Learning Perspective,” by C.R. Farrar and K. Worden, John Wiley and Sons, New York, 2013), a better approach is
to use Edge Computing. Edge Computing takes the raw data, which could be MB or GB per second, and extracts features. Features are
attributes of the signal that preserve the essential physics of the signal but reduce the data density by a very large amount (up
to a factor of one million). After the feature extraction step, the data has a data rate of approximately 10KB or 100KB per second.
Next comes the classification step, which further reduces data by classifying data into at least two bins: nominal behavior or
off-nominal or abnormal behavior. For example, in monitoring a machine tool in a factory, if the machine tool is behaving normally,
there is nothing to report and therefore no data needs to be sent or transferred anywhere. Only the abnormal condition data needs
to be sent along with a description of the problem. This is what Edge Computing accomplishes and it accomplishes this right where
the data is being collected using relatively small computational and memory resources (For example our systems have a 1GHz processor
and one few GB of RAM plus up to 32 GB of storage – which is less computational power than the average smart phone.). so
considering all of these technical aspects, we are able to assert that our Edge Computing process is more efficient in terms of
computational power and memory as compared to a cloud-based solution, that it only sends along the information (not just data)
that is really needed, and it can still interact with cloud based services to provide data sharing across different platforms.
The second source of competition is from
startups who are in the edge computing space. The most prominent example is FogHorn Systems Inc. There will be additional startups
that will specifically target the edge computing space as the investor awareness and the technical focus shifts from cloud computing
to edge computing. Whereas other startups focus on development of proprietary tools for edge computing, our solutions will use
open source tools but will still create proprietary algorithms and software content for clients and customers. We feel this methodology
of creating proprietary solutions using open source tools will allow us to rapidly address current and future customer needs.
Government Regulation
At present, we do not require any governmental
approvals of any of our products or services.
Environmental Laws
At present, we are not regulated by any
environmental laws.
Research and Development
Other than expenses for legal, accounting,
audit, tax preparation, intellectual property (IP), and other overhead expenses such rent, most of our funds are spent on technology
development, product development, and research and development. We are an emerging growth, early-stage, technology company and,
as such, most of our expenditures are aimed at innovation and product development.
We have a technology maturation model so
that we avoid doing work on technologies that are too early and too new and belong in a pure search environment. We rely heavily
on our research partners such as universities and National Labs for such early stage work. When the technology is ready to leave
the lab, we take over the further development. Along the way we expect to file additional IP and otherwise protect technology by
using trademarks, for example.
The efforts in research and development
have already resulted in significant customer interest in various market verticals including industrial, automotive, aerospace,
agricultural, infrastructure, and power generation.
All the present projects that we are working
on internally as research and development projects will go forward, so we do not have any projects in the category of projects
that have incurred significant expense but that will not result in present or future products.
Intellectual Property
On February 5, 2018, we entered into a
Non-Exclusive Patent License Agreement with MIT. The agreement, which was effective February 1, 2018, granted to us a royalty-bearing
non-exclusive license under U.S. Patent Nos. 8344724 (“Non-Intrusive Monitoring of Power and Other Parameters” issued
January 1, 2013), 14/263407 (“Non-Intrusive Monitoring” filed April 28, 2014), and Patent Cooperation Treaty Serial
No. PCT/US2016/057165 (“Noncontact Power Sensing” filed October 14, 2016) during the term of the agreement. The term
of the agreement was from the effective date until the expiration or abandonment of all issued patents and filed patent applications
licensed pursuant to the agreement, unless terminated earlier in accordance with the agreement.
Under the agreement, we were required to
make a first commercial sale of a “LICENSED PRODUCT” and/or a first commercial performance of a “LICENSED PROCESS,”
as defined in the agreement, on or before September 30, 2018. We had negotiated revenue targets with MIT which would determine
annual royalty payments. The 2018 minimum revenue target for the sale of products and services incorporating the MIT technology
was $100,000. This minimum revenue amount would increase in subsequent years.
Within 30 days of invoicing, a non-refundable
license issue fee of $10,000 was paid by us to MIT. Pursuant to the agreement, we were required to pay to MIT additional patent
maintenance fees in years beyond 2018.
Pursuant to the agreement, we were required
to pay to MIT a running royalty of 2% of “NET SALES,” as defined in the agreement made in the calendar years 2018,
2019, and 2020. For “NET SALES” made in the calendar year 2021 and every calendar year thereafter through the term
of the agreement, we were required to pay to MIT a running royalty of 4%.
On October 31, 2018, we sent written notice
of our intent to terminate the agreement with an effective date of termination of April 30, 2019. Since none of the technology
licensed to us by MIT had been used by us in any of our products and we had
been investing
in the development of our own intellectual property, we determined the technology that was licensed from MIT wasn’t necessary
in the near term.
Due to this, the written notice sent by us expressed a desire by our management to renegotiate the
terms of the agreement with MIT.
MIT declined to renegotiate the terms of
the agreement and, on December 6, 2018, we received a notice of termination from MIT due to non-payment of fees. As of December
6, 2018, the agreement was terminated, fees are no longer accruing, and the fees owed to MIT as of December 6, 2018 are still owing
as of the date of this prospectus. Despite the
termination of the Agreement, we remain
active with MIT as a member of the MIT Startup Exchange (STEX). The purpose of STEX is to promote collaboration and partnerships
between MIT-connected startups and members of MIT’s Industrial Liaison Program. We remain open to future mutually acceptable
agreements with MIT.
We
continue to develop our proprietary algorithms and plan to protect them through a combination of trade secret, copyright, and patents.
Customers
Due to our status of a start-up, at the
moment, we depend on a few major customers. This should change as we implement plans for future growth.
Employees
We have no full or part-time employees;
however, we do have contractor employees (1099 basis) who are working daily on the core business activities of the business and
have been doing so since the beginning of the business formation. During the second quarter of 2019, we plan on transitioning contractors
such as Clifford Emmons and Karen McNemar to a W-2 basis. Clifford Emmons, our CEO, President, interim CFO, and director, currently
devotes approximately 35 hours a week to our business and Karen McNemar, our COO, currently devotes approximately 40 hours a week
to our business. At the present time, except for the funding received from Cambridge MedSpace LLC in the form of a secured note,
there are no conflicts of interest between the Company and any of our officers and directors. This was determined as follows: i)
none of their outside activities are soliciting business from our customers or business contacts; ii) they are not soliciting our
investors to invest in other ventures; and iii) they are not soliciting our contract employees to leave us and join other efforts.
In 2019 we anticipate hiring 3-5 full time employees. At present, all our business services are provided by outside contractors.
Properties
We currently do not own any properties.
LEGAL PROCEEDINGS
At the present time we are not involved
or engaged in any legal proceedings. From time to time however, we may become involved in various lawsuits and legal proceedings,
which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result
in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal
proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial
condition or operating results.
MANAGEMENT
Current Management
The following table sets forth information
concerning our directors and executive officers:
Name
|
|
Position
|
|
Age
|
Executive Officers
:
|
|
|
|
|
Clifford L. Emmons
|
|
Chief Executive Officer, President, and Interim Chief Financial Officer
|
|
57
|
Karen McNemar
|
|
Chief Operating Officer
|
|
49
|
Antony Coufal
|
|
Chief Technology Officer and President of HereLab
|
|
42
|
|
|
|
|
|
Directors
:
|
|
|
|
|
Clifford L. Emmons
|
|
Director
|
|
57
|
Vidhyadhar Mitta
|
|
Director
|
|
46
|
Directors are elected to serve until the
next annual meeting of stockholders and until their successors are elected and qualified. Directors are elected by a plurality
of the votes cast at the annual meeting of stockholders and hold office until the expiration of the term for which he or she was
elected and until a successor has been elected and qualified.
A majority of the authorized number of
directors constitutes a quorum of the Board of Directors for the transaction of business. The directors must be present at the
meeting to constitute a quorum. However, any action required or permitted to be taken by the Board of Directors may be taken without
a meeting if all members of the Board of Directors individually or collectively consent in writing to the action.
Business Experience of Executive
Officers and Directors
The principal occupation and business experience
during the past five years for our executive officers and directors is as follows:
Clifford L. Emmons:
Mr. Emmons
has served as our Chief Executive Officer, President, Interim Chief Financial Officer, and director since June 4, 2018. From 1995
to 2017, Mr. Emmons worked for Medtronic,
a global leader in medical technology, services,
and solutions,
where he served in various capacities including several Vice President and Director positions. Mr. Emmons
is also the founder of AHI, LLC, a consultancy firm. Mr. Emmons received an Executive Certificate in Strategy & Innovation
from MIT, a Masters of Science in Management Engineering from the University of Bridgeport, a Bachelor of Science in Electrical
Engineering from the University of New Haven, and a Bachelor of Science in Mechanical Engineering from the University of Connecticut.
Karen McNemar:
Ms. McNemar
has served as our Chief Operating Officer since September 20, 2018. From 1998 until August 2017, Ms. McNemar served in many capacities
for Medtronic which included as a Senior Director of R&D Operations.
Ms. McNemar
is a collaborative strategic global business leader with extensive experience in New Product Development and Operations, building
strong and effective diverse teams across organizations at all levels. Ms. McNemar is also a trusted advisor, recognized for successful
process and program management, with a focus on leading complex initiatives and analyzing data and processes to identify solutions
to increase organizational productivity and performance.
Ms. McNemar received her
Bachelor
of Science in Industrial Engineering and Operations Research.
Antony Coufal:
Mr.
Coufal has served as our Chief Technology Officer since April 23, 2018. From December 2008 to December 2017, Mr. Coufal
served as the Chief Executive Officer of INTEX Corp., a telecommunications contractor.
Mr.
Coufal is a multicultural leader with strong business acumen and diverse technical skills who has 20+ years of experience
launching several successful technology focused corporations serving government, Fortune 500, and global entities requiring
innovative solutions in engineering, construction, intelligent security, IT & telecom, industrial electrical and HVAC in
numerous US and LATAM markets. He is a graduate of Rensselaer Polytechnic Institute with degrees in Engineering Sciences and
Business Administration.
Vidhyadhar Mitta:
Mr. Mitta
has served as a director of the Company since the closing of the reverse acquisition on July 28, 2017. Mr. Mitta has also served
as a director of OXYS since its inception on August 4, 2016. Since 2000, he has been the founder and President of Synergic Solutions
Inc., a software development company that designs custom software for a variety of industries including radio-medicine and associate
allied health fields. In his position as President, Mr. Mitta has responsibility for all aspects of Synergic Solutions including
technical program guidance, employee supervision, business development, and profit and loss responsibility. Mr. Mitta received
a BS in Information Science & Technology from BMS College of Engineering in 1995.
Legal Proceedings
During the past ten years there have been
no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation
of the ability and integrity of any of our directors or executive officers, and none of these persons has been involved in any
judicial or administrative proceedings resulting from involvement in mail or wire fraud or fraud in connection with any business
entity, any judicial or administrative proceedings based on violations of federal or state securities, commodities, banking or
insurance laws or regulations, or any disciplinary sanctions or orders imposed by a stock, commodities or derivatives exchange
or other self-regulatory organization.
Family Relationships
There are no family relationships between
any of our directors and executive officers.
Director Independence
We are not currently subject to listing
requirements of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the
board of directors be “independent” and, as a result, we are not at this time required to have our Board of Directors
comprised of a majority of “independent directors.”
We currently have not established any committees
of the Board of Directors. Our Board of Directors may designate from among its members an executive committee and one or more other
committees in the future. We do not have a nominating committee or a nominating committee charter. Further, we do not have a policy
with regard to the consideration of any director candidates recommended by security holders. To date, other than as described above,
no security holders have made any such recommendations. The entire Board of Directors performs all functions that would otherwise
be performed by committees. Given the present size of our board it is not practical for us to have committees. If we are able to
grow our business and increase our operations, we intend to expand the size of our board and allocate responsibilities accordingly.
Certain Relationships and Related
Transactions
Upon the Closing of the HereLab SEA, we
issued to Mr. Phillips, a former director and officer, 1,500,000 shares of our Common Stock and appointed Mr. Phillips as a director
of the Company.
We entered into a Consulting Agreement
dated May 22, 2018 with Mr. Phillips pursuant to which we agreed to pay him $7,000 per month in consulting fees. The term of the
agreement was month-to-month for one year.
We entered into a Settlement Agreement
dated November 5, 2018 with Patrick Phillips pursuant to which we agreed to issue to Mr. Phillips, on January 1, 2019, 104,673
shares of the Company’s Common Stock in exchange for release of the Company by Mr. Phillips of any amounts owed to him by
us or any of our subsidiaries.
We entered into a lease agreement with
a former officer and director and current shareholder on August 1, 2017 which began on January 1, 2018 and terminated on December
31, 2018. We entered into a new lease agreement on March 12, 2019, which began on January 1, 2019 and will terminate on June 30,
2019. Pursuant to the lease, we are obligated to pay the landlord monthly installments of $2,000 for a total lease payment of $12,000
in 2019.
On July 31, 2018, we entered into Amendment
No. 1 to Consulting Agreement dated December 1, 2017 with Accelerated Healthcare Innovations LLC which changed the fee from a flat
fee to an hourly fee not to exceed $24,000 in the aggregate and also eliminated the obligation of the Company to issue to the Consultant
any equity compensation pursuant to the agreement.
On March 1, 2018, we entered into a Consulting
Agreement with Accelerated Healthcare Innovations LLC. The term of the agreement is until the completion of the Services, as defined
in the agreement or until early termination upon 10 days’ written notice given by either party. Pursuant to the agreement,
the consultant agreed to provide business consulting services to us in exchange for a flat fee of $48,000 and the issuance of 60,000
shares of our Common Stock.
On July 31, 2018, we entered into Amendment
No. 1 to Consulting Agreement dated March 1, 2018 with Accelerated Healthcare Innovations LLC which changed the fee from a flat
fee to an hourly fee not to exceed $48,000 in the aggregate and also eliminated the obligation of the Company to issue to the Consultant
any equity compensation pursuant to the agreement.
On July 31, 2018, we entered into the Termination
Agreement with Accelerated Healthcare Innovations LLC which terminated the Consulting Agreement, as amended, dated March 1, 2018
effective June 4, 2018.
On July 1, 2018, we entered into a Consulting
Agreement with Karen McNemar, our Chief Operating Officer. The term of the agreement was until the completion of the Services,
as defined in the agreement or until early termination upon 10 days’ written notice given by either party. Pursuant to the
agreement, Ms. McNemar agreed to provide business consulting services to us in exchange for a flat fee of $12,000 and the issuance
of 9,000 shares of our Common Stock.
On October 5, 2018, we entered into Amendment
No. 1 to the Consulting Agreement with Karen McNemar which eliminated the obligation of the Company to provide to Ms. McNemar equity
compensation under her original Consulting Agreement dated July 1, 2018.
On April 23, 2018 entered into a Consulting
Agreement with Antony Coufal pursuant to which Mr. Coufal was appointed as our Chief Technology Officer effective as of April 23,
2018. For the first three months of the agreement, we were required to pay to Mr. Coufal a monthly consulting fee of $3,600, which
would rise to $6,300 per month after the first three months. In addition, Mr. Coufal will be eligible to participate in the Company’s
Stock Incentive Plan.
On October 9, 2018, we entered into Amendment
No. 1 to the Consulting Agreement with Antony Coufal, our Chief Technical Officer and President of HereLab, Inc. The amendment
clarified the vesting schedule of equity compensation awarded to Mr. Coufal under his original Consulting Agreement dated April
23, 2018 and also provided for acceleration of vesting upon the occurrence of a “Change of Control,” as defined in
the amendment and an uplisting to a senior exchange.
On January 22, 2019, we entered into a
Securities Purchase Agreement with Cambridge MedSpace, LLC, a Massachusetts limited liability company for the purchase of a 5%
Secured Convertible Note in the principal amount of $55,000. The note is convertible, in whole or in part, into shares of our Common
Stock, at any time at a rate of $0.65 per share with fractions rounded up to the nearest whole share, unless paid in cash at our
election. The note bears interest at a rate of 5% per annum and interest payments will be made on an annual basis. The note matures
January 22, 2020. The note is governed by the SPA and is secured by all our assets (but is not a senior secured note) pursuant
to the Security Agreement. In addition to the issuance of the note, we issued to Cambridge MedSpace warrants to purchase one share
of our Common Stock for 50% of the number of shares of Common Stock issuable upon conversion of the note. Each warrant is immediately
exercisable at $0.75 per share and expires on January 22, 2024. The Lender is owned by shareholders of the Company, or their affiliates,
including Clifford Emmons, our Chief Executive Officer, Interim Chief Financial Officer, and director.
EXECUTIVE COMPENSATION
The following table sets forth information
concerning the annual compensation awarded to, earned by, or paid to the following named executive officers for all services rendered
in all capacities to our company and its subsidiaries for the years ended December 31, 2018 and 2017.
Summary Compensation Table
Name and principal position
|
|
Year
|
Salary
($)
|
Stock Awards
($)
|
|
All other
compensation
($)
|
|
Total
($)
|
Clifford Emmons
(1)
|
|
2018
|
151,283
(2)(3)
|
179,409
(4)
|
|
0
|
|
330,692
|
|
|
|
2017
|
0
|
0
|
|
0
|
|
0
|
|
Nevan Hanumara
(5)
|
|
2018
|
10,000
(6)
|
0
|
|
0
|
|
10,000
|
|
|
|
2017
|
17,451
(7)
|
0
|
|
0
|
|
17,451
|
|
Giro DiBiase
(8)
|
|
2018
|
0
|
0
|
|
0
|
|
0
|
|
|
|
2017
|
0
|
0
|
|
25,000
(9)
|
|
25,000
|
|
Patrick Phillips
(10)
|
|
2018
|
54,754
|
31,402
|
|
0
|
|
86,156
|
|
|
|
2017
|
0
|
0
|
|
0
|
|
0
|
|
Antony Coufal
(11)
|
|
2018
|
92,903
(12)
|
135,617
(13)
|
|
0
|
|
228,520
|
|
|
|
2017
|
0
|
0
|
|
0
|
|
0
|
|
Karen McNemar
(14)
|
|
2018
|
55,541
(15)
|
60,720
(16)
|
|
0
|
|
116,261
|
|
|
|
2017
|
0
|
0
|
|
0
|
|
0
|
|
|
(1)
|
Mr. Emmons was appointed as our CEO, President, and interim CFO on June 4, 2018
|
|
(2)
|
$46,283 of Mr. Emmons’ salary for 2018 was owed to Accelerated Healthcare Innovations LLC, a limited liability company owned by Mr. Emmons.
|
|
(3)
|
$110,840 of Mr. Emmons’ salary for 2018 was accrued and unpaid.
|
|
(4)
|
Represents shares which have been granted but were unvested at December 31, 2018.
|
|
(5)
|
Mr. Hanumara served as our CEO from February 28, 2018 until June 4, 2018.
|
|
(6)
|
Effective February 28, 2018, our Board of Directors approved the payment of $5,000 in consulting fees per month to Mr. Hanumara.
|
|
(7)
|
On July 28, 2017, our Board of Directors approved the payment of $2,500 in consulting fees per month to Mr. Hanumara.
|
|
(8)
|
Mr. DiBiase served as our CEO from July 28, 2017 until February 28, 2018.
|
|
(9)
|
Consisted of fees paid for misc. management, business development, administrative, accounting, and operational services rendered on a consulting basis.
|
|
(10)
|
Mr. Phillips served as a director and V.P. of Product Management until September 20, 2018.
|
|
(11)
|
Mr. Coufal was appointed as our CTO on April 23, 2018.
|
|
(12)
|
$74,196 of Mr. Coufal’s salary for 2018 was accrued and unpaid.
|
|
(13)
|
Represents shares which have been granted but were unvested at December 31, 2018.
|
|
(14)
|
Ms. McNemar was appointed as our COO effective as of September 20, 2018.
|
|
(15)
|
$52,479 of Ms. McNemar’s salary for 2018 was accrued and unpaid.
|
|
(16)
|
Represents shares which have been granted but were unvested at December 31, 2018.
|
Emmons Consulting Agreement
On March 11, 2019, the Company’s
Board of Directors (with Mr. Emmons abstaining) approved the Consulting Agreement dated effective June 4, 2018 with Clifford Emmons,
the Company’s Chief Executive Officer, Interim Chief Financial Officer, and director (the “
Emmons Agreement
”).
The term of the Emmons Agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the
agreement and is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by Mr.
Emmons pursuant to the Emmons Agreement are those customary for the positions in which he is serving.
Mr. Emmons shall receive a monthly fee
of $15,000 which accrues unless converted into shares of Common Stock of the Company at a conversion rate specified in the Emmons
Agreement. Until the Company closes a minimum $500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital
raise, $5,000 of the monthly fee will be paid to Mr. Emmons in cash and the remainder will continue to accrue. Upon the closing
of a capital raise of at least $2,000,000, the entire monthly fee will be paid to Mr. Emmons in cash and all accrued and unpaid
monthly fees will be paid by the Company within one year of the closing of such a capital raise.
As of the effective date, the Company shall
issue to Mr. Emmons an aggregate of 3,060,000 shares of the Company’s Common Stock which vest as follows:
|
1.
|
560,000 shares on the first-year anniversary of the effective date;
|
|
2.
|
1,000,000 shares on the second-year anniversary of the effective date; and
|
|
3.
|
1,500,000 shares on the third-year anniversary of the effective date.
|
The shares are granted under the 2019 Plan.
Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as
defined in the Emmons Agreement) or the listing of the Company’s Common Stock on a senior exchange.
Coufal Amended and Restated Consulting
Agreement
On March 11, 2019, the Company’s
Board of Directors approved the Amended and Restated Consulting Agreement dated effective April 23, 2018 with Antony Coufal, the
Company’s Chief Technology Officer (the “
Coufal Agreement
”). The term of the Coufal Agreement is for three
years beginning as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable for
one-year terms upon the consent of the parties. The services to be provided by Mr. Coufal pursuant to the Coufal Agreement are
those customary for the position in which he is serving.
Mr. Coufal shall receive a monthly fee
of $9,375 which accrues unless converted into shares of Common Stock of the Company at a conversion rate specified in the Coufal
Agreement. Until the Company closes a minimum $500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital
raise, $3,125 of the monthly fee will be paid to Mr. Coufal in cash and the remainder will continue to accrue. Upon the closing
of a capital raise of at least $2,000,000, the entire monthly fee will be paid to Mr. Coufal in cash and all accrued and unpaid
monthly fees will be paid by the Company within one year of the closing of such a capital raise.
As of the effective date, the Company shall
issue to Mr. Coufal an aggregate of 1,800,000 shares of the Company’s Common Stock which vest as follows:
1.
|
300,000 shares on the first-year anniversary of the effective date;
|
2.
|
600,000 shares on the second-year anniversary of the effective date; and
|
3.
|
900,000 shares on the third-year anniversary of the effective date.
|
The shares are granted under the 2017 Stock
Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change
of Control (as defined in the Coufal Agreement) or the listing of the Company’s Common Stock on a senior exchange.
McNemar Consulting Agreement
On March 11, 2019, the Company’s
Board of Directors approved the Consulting Agreement dated effective October 1, 2018 with Karen McNemar, the Company’s Chief
Operating Officer (the “
McNemar Agreement
”). The term of the McNemar Agreement is for three years beginning
as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable for one-year terms
upon the consent of the parties. The services to be provided by Ms. McNemar pursuant to the McNemar Agreement are those customary
for the position in which she is serving.
Ms. McNemar shall receive a monthly fee
of $12,750 which accrues unless converted into shares of Common Stock of the Company at a conversion rate specified in the McNemar
Agreement. Until the Company closes a minimum $500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital
raise, $4,250 of the monthly fee will be paid to Ms. McNemar in cash and the remainder will continue to accrue. Upon the closing
of a capital raise of at least $2,000,000, the entire monthly fee will be paid to Ms. McNemar in cash and all accrued and unpaid
monthly fees will be paid by the Company within one year of the closing of such a capital raise.
As of the effective date, the Company shall
issue to Ms. McNemar an aggregate of 2,409,000 shares of the Company’s Common Stock which vest as follows:
|
1.
|
409,000 shares on the first-year anniversary of the effective date;
|
|
2.
|
800,000 shares on the second-year anniversary of the effective date; and
|
|
3.
|
1,200,000 shares on the third-year anniversary of the effective date.
|
The shares are granted under the 2017 Stock
Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change
of Control (as defined in the McNemar Agreement) or the listing of the Company’s Common Stock on a senior exchange.
Phillips Consulting Agreement
On August 22, 2017, OXYS entered into a
Consulting Agreement with HereLab (the “
August 2017 Agreement
”). Effective as of August 22, 2017, HereLab, OXYS,
and Mr. Phillips entered into a Novation Agreement pursuant to which Mr. Phillips assumed the obligations of HereLab under the
August 2017 Agreement and HereLab was discharged from the August 2017 Agreement. On May 22, 2018, Mr. Phillips entered into a Consulting
Agreement with the Company (the “
May 2018 Agreement
”).
Pursuant to the May 2018 Agreement, the
Company was obligated to pay to Mr. Phillips $7,000 per month payable upon invoicing, commencing June 2018. In addition to the
cash compensation, Mr. Phillips was entitled to participate in the Company’s Stock Incentive Plan according to the following
vesting schedule:
|
·
|
200,000 shares of the Company’s Common Stock in December 2018;
|
|
·
|
300,000 shares of the Company’s Common Stock in December 2019; and
|
|
·
|
500,000 shares of the Company’s Common Stock in December 2020.
|
Effective September 20, 2018, Mr. Phillips
resigned from all positions within the Company, HereLab, and OXYS and the August 2017 Agreement and the May 2018 Agreement were
mutually terminated by all parties.
Equity Awards
The following table sets forth information
concerning as of the year ended December 31, 2018 for our named executive officers.
Outstanding Equity Awards at Fiscal Year-End
|
|
Stock awards
|
Name
|
|
Number of shares or units of stock that have not vested
(#)
|
|
Market value of shares of units of stock that have not vested
($)
|
|
Equity
incentive
plan awards: Number of
unearned
shares, units or other rights that have not vested
(#)
|
|
Equity
incentive
plan awards: Market or payout value of
unearned
shares, units or other rights that have not vested
($)
|
Clifford Emmons
|
|
323,726
|
|
74,457
|
|
323,726
|
|
74,457
|
Nevan Hanumara
|
|
0
|
|
–
|
|
0
|
|
–
|
Giro DiBiase
|
|
0
|
|
–
|
|
0
|
|
–
|
Patrick Phillips
|
|
0
|
|
–
|
|
0
|
|
–
|
Antony Coufal
|
|
207,124
|
|
47,639
|
|
207,124
|
|
47,639
|
Karen McNemar
|
|
103,091
|
|
23,711
|
|
103,091
|
|
23,711
|
Compensation of Directors
The following table sets forth information
concerning the compensation awarded to, earned by, or paid to the following directors for all services rendered in all capacities
to our company and its subsidiaries for the year ended December 31, 2018. Except for Messrs. Hanumara, Phillips, and Emmons (whose
compensation is disclosed above), this table includes any person who served as a director at any time during fiscal 2018.
Except as described below, we have not
entered into any employment or compensation agreements or arrangements with Mr. Mitta for his services as a director of our company.
Director Compensation
Name
|
|
Fees earned or paid in cash
($)
|
|
Total
($)
|
Vidhyadhar Mitta
|
|
0
|
|
0
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
The following table and footnotes thereto
sets forth information regarding the number of shares of common stock beneficially owned by (i) each director and named executive
officer of our company, (ii) each person known by us to be the beneficial owner of 5% or more of its issued and outstanding shares
of common stock, and (iii) named executive officers, executive officers, and directors of the Company as a group. In calculating
any percentage in the following table of common stock beneficially owned by one or more persons named therein, the following table
assumes 41,810,324 shares of common stock issued and outstanding. Unless otherwise further indicated in the following table, the
footnotes thereto and/or elsewhere in this prospectus, the persons and entities named in the following table have sole voting and
sole investment power with respect to the shares set forth opposite the shareholder’s name, subject to community property
laws, where applicable. Unless as otherwise indicated in the following table and/or the footnotes thereto, the address of each
person beneficially owning in excess of 5% of the outstanding common stock named in the following table is: 705 Cambridge Street,
Cambridge, MA 02141.
Name and Address of Beneficial Owner
|
|
Amount and
Nature of
Beneficial
Ownership
(1)
|
|
|
Percent
of Class
(1)
|
|
Named Executive Officers and Directors
|
|
|
|
|
|
|
|
|
Nevan Hanumara
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
Clifford Emmons
|
|
|
681,468
|
(2)
|
|
|
1.60%
|
|
Giro DiBiase
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
Patrick Phillips
|
|
|
1,565,006
|
|
|
|
3.74%
|
|
Antony Coufal
|
|
|
300,000
|
(3)
|
|
|
*
|
|
Karen McNemar
|
|
|
0
|
|
|
|
*
|
|
Vidhyadhar Mitta
|
|
|
1,736,843
|
|
|
|
4.15%
|
|
Executive Officers, Named Executive Officers, and Directors as a Group (7 Persons)
|
|
|
10,283,317
|
|
|
|
24.03%
|
|
5% Beneficial Holders (Not Named Above)
|
|
|
|
|
|
|
|
|
Nutan Dave
705 Cambridge Street
Cambridge, MA 02141
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
Sergey Gogin
3080 W 1
st
Apt 601
Brooklyn, NY 11224
|
|
|
4,557,240
|
(4)
|
|
|
10.11%
|
|
Dmitriy Shapiro
135 Oceana Dr E Apt 4E
Brooklyn, NY 11235
|
|
|
2,202,632
|
(5)
|
|
|
5.22%
|
|
*Less than 1%
|
(1)
|
Under Rule 13d-3 of the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the number of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the above table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on the date of this prospectus.
|
|
(2)
|
Includes 36,667 shares issuable upon the exercise of warrants issued to Cambridge MedSpace LLC, an entity of which Mr. Emmons is an owner. Also includes 84,801 shares issuable upon the conversion of a note issued to Cambridge MedSpace LLC. Lastly, includes 560,000 shares of Common Stock which fully-vest on June 4, 2019.
|
|
(3)
|
Includes 300,000 shares of Common Stock which fully-vest on April 23, 2019.
|
|
(4)
|
Includes 384,615 shares issuable upon the exercise of warrants. Also includes 125,000 shares issuable upon the exercise of warrants issued to YVSGRAMORA, LLC, an entity of which Mr. Gogin is an owner. Also includes 2,513,151 shares issuable upon the conversion of a note issued to Mr. Gogin. Lastly, includes 251,316 shares issuable upon the conversion of a note issued to YVSGRAMORA, LLC.
|
|
(5)
|
Includes 526,316 shares owned by Catalytic Capital LLC, an entity of which Mr. Shapiro is the managing partner. Also includes 125,000 shares issuable upon the exercise of warrants issued to Catalytic Capital LLC. Lastly, includes 251,316 shares issuable upon the conversion of a note issued to Catalytic Capital LLC.
|
SELLING STOCKHOLDERS
This prospectus relates to the possible
resale by the selling stockholders named below of shares of the Company’s common stock. References in this prospectus to
the “selling stockholder(s)” includes the selling stockholders listed below, and any donees, pledgees, transferees
or other successors in interest selling shares received after the date of this prospectus from a selling stockholder as a gift,
pledge or other non-sale related transfer.
The selling stockholders will offer their
shares at prevailing market or privately negotiated prices including (without limitation) in one or more transactions that may
take place by ordinary broker’s transactions, privately-negotiated transactions or through sales to one or more dealers for
resale or at prevailing market if a market should develop.
The distribution of the selling stockholders’
shares may be effected in one or more transactions that may take place through customary brokerage channels, in privately-negotiated
sales, by a combination of these methods or by other means. The selling stockholders may from time to time offer their shares through
underwriters, brokers-dealers, agents or other intermediaries. Usual and customary or specifically negotiated brokerage fees or
commissions may be paid by the selling stockholders in connection with sales of the shares.
The distribution of the shares by the selling
stockholders may be effected in one or more transactions that may take place through customary brokerage channels, in privately
negotiated sales; by a combination of these methods; or by other means. We do not know how long the selling stockholders will hold
the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders
regarding the sale of any of the shares. The Company will not receive any portion or percentage of any of the proceeds from the
sale of the shares.
The following table sets forth ownership
of shares held by each person who is a selling stockholder.
Name
|
|
Amount
Beneficial
Ownership
Before
Offering
|
|
|
Percentage
of Common
Stock
Owned
Before
Offering
1
|
|
|
Amount to be
Offered for the
Security Holder’s
Account
|
|
|
Amount to
be
Beneficially
Owned
After
Offering
1
|
|
|
Percentage
of Common
Stock
Owned
After
Offering
2
|
|
Alta Investments, LLC
3
|
|
|
1,294,200
|
|
|
|
3.10%
|
|
|
|
1,290,000
|
|
|
|
4,200
|
|
|
|
*
|
|
Matthew Bechtel
|
|
|
1,250,010
|
|
|
|
2.99%
|
|
|
|
1,250,010
|
|
|
|
0
|
|
|
|
0%
|
|
Nutan V. Dave
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
|
|
3,000,000
|
|
|
|
0
|
|
|
|
0%
|
|
Deerfield Valley Investments, LLC
|
|
|
99,990
|
|
|
|
*
|
|
|
|
99,990
|
|
|
|
0
|
|
|
|
0%
|
|
Giro DiBiase
4
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
|
|
2,934,558
|
|
|
|
65,442
|
|
|
|
*
|
|
Sergey Gogin
|
|
|
1,283,158
|
|
|
|
3.07%
|
|
|
|
1,283,158
|
|
|
|
0
|
|
|
|
0%
|
|
Robert B. Greene Revocable Trust
|
|
|
999,990
|
|
|
|
2.39%
|
|
|
|
999,990
|
|
|
|
0
|
|
|
|
0%
|
|
Nevan Hanumara
|
|
|
3,000,000
|
|
|
|
7.18%
|
|
|
|
2,934,558
|
|
|
|
65,442
|
|
|
|
*
|
|
Imperio Capital, LLC
|
|
|
1,290,000
|
|
|
|
3.09%
|
|
|
|
1,290,000
|
|
|
|
0
|
|
|
|
0%
|
|
Carolyn LaMain
|
|
|
1,290,000
|
|
|
|
3.09%
|
|
|
|
1,290,000
|
|
|
|
0
|
|
|
|
0%
|
|
Liberator Holding, LLC
|
|
|
900,000
|
|
|
|
2.15%
|
|
|
|
900,000
|
|
|
|
0
|
|
|
|
0%
|
|
MJM Companies, LLC
|
|
|
300,010
|
|
|
|
*
|
|
|
|
300,010
|
|
|
|
0
|
|
|
|
0%
|
|
Joanne Maser
|
|
|
399,000
|
|
|
|
*
|
|
|
|
399,000
|
|
|
|
0
|
|
|
|
0%
|
|
Joseph Mattia
5
|
|
|
99,990
|
|
|
|
*
|
|
|
|
99,990
|
|
|
|
0
|
|
|
|
0%
|
|
Lenny Morales
|
|
|
1,220,000
|
|
|
|
2.92%
|
|
|
|
1,220,000
|
|
|
|
0
|
|
|
|
0%
|
|
Mountain Ranch Partners, Inc.
|
|
|
1,299,990
|
|
|
|
3.11%
|
|
|
|
1,299,990
|
|
|
|
0
|
|
|
|
0%
|
|
Timothy Murphy
|
|
|
99,990
|
|
|
|
*
|
|
|
|
99,990
|
|
|
|
0
|
|
|
|
0%
|
|
Nata Solutions, Inc.
|
|
|
1,290,000
|
|
|
|
3.09%
|
|
|
|
1,290,000
|
|
|
|
0
|
|
|
|
0%
|
|
Mary Peck
|
|
|
1,290,000
|
|
|
|
3.09%
|
|
|
|
1,290,000
|
|
|
|
0
|
|
|
|
0%
|
|
Michael & Heidi Salaman
|
|
|
650,010
|
|
|
|
1.55%
|
|
|
|
650,010
|
|
|
|
0
|
|
|
|
0%
|
|
Laszlo Schwartz
|
|
|
1,403,010
|
|
|
|
3.36%
|
|
|
|
1,403,010
|
|
|
|
0
|
|
|
|
0%
|
|
Dmitriy Shapiro
|
|
|
1,290,000
|
|
|
|
3.09%
|
|
|
|
1,290,000
|
|
|
|
0
|
|
|
|
0%
|
|
Valerie Vekkos Trust
|
|
|
999,990
|
|
|
|
2.39%
|
|
|
|
999,990
|
|
|
|
0
|
|
|
|
0%
|
|
Joseph Bardenheier
|
|
|
100,000
|
|
|
|
*
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0%
|
|
Catalytic Capital, LLC
|
|
|
526,316
|
|
|
|
1.26%
|
|
|
|
526,316
|
|
|
|
0
|
|
|
|
0%
|
|
Pat Catizone
|
|
|
200,000
|
|
|
|
*
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0%
|
|
Kurtis Hughes
6
|
|
|
100,000
|
|
|
|
*
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0%
|
|
Gang Lian & Xiao Ning Wang
|
|
|
200,000
|
|
|
|
*
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0%
|
|
Charles McSorley
|
|
|
100,000
|
|
|
|
*
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0%
|
|
Thomas D. Murphy
|
|
|
500,000
|
|
|
|
1.20%
|
|
|
|
500,000
|
|
|
|
0
|
|
|
|
0%
|
|
Thomas Ott
|
|
|
100,000
|
|
|
|
*
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0%
|
|
Dinesh Patel
|
|
|
1,052,632
|
|
|
|
2.52%
|
|
|
|
1,052,632
|
|
|
|
0
|
|
|
|
0%
|
|
William Peck
|
|
|
526,316
|
|
|
|
1.26%
|
|
|
|
526,316
|
|
|
|
0
|
|
|
|
0%
|
|
Eduard Pinskiy
|
|
|
105,263
|
|
|
|
*
|
|
|
|
105,263
|
|
|
|
0
|
|
|
|
0%
|
|
Seymore & Mark Rubin
|
|
|
500,000
|
|
|
|
1.20%
|
|
|
|
500,000
|
|
|
|
0
|
|
|
|
0%
|
|
Michael Semidubersky
|
|
|
105,263
|
|
|
|
*
|
|
|
|
105,263
|
|
|
|
0
|
|
|
|
0%
|
|
Roman Shteynshlyuger
|
|
|
210,526
|
|
|
|
*
|
|
|
|
210,526
|
|
|
|
0
|
|
|
|
0%
|
|
KDT Real Estate Holding, LLC
|
|
|
200,000
|
|
|
|
*
|
|
|
|
200,000
|
|
|
|
0
|
|
|
|
0%
|
|
Daniel Tulbovich
|
|
|
105,263
|
|
|
|
*
|
|
|
|
105,263
|
|
|
|
0
|
|
|
|
0%
|
|
Vidhyadhar Mitta
7
|
|
|
1,736,843
|
|
|
|
4.15%
|
|
|
|
1,736,843
|
|
|
|
0
|
|
|
|
0%
|
|
Daniel & Maryellen Whittier
|
|
|
100,000
|
|
|
|
*
|
|
|
|
100,000
|
|
|
|
0
|
|
|
|
0%
|
|
Maxim Zakharchenko
|
|
|
105,263
|
|
|
|
*
|
|
|
|
105,263
|
|
|
|
0
|
|
|
|
0%
|
|
Denis Zaslavskiy
|
|
|
105,263
|
|
|
|
*
|
|
|
|
105,263
|
|
|
|
0
|
|
|
|
0%
|
|
Draco Financial LLC
|
|
|
350,000
|
|
|
|
*
|
|
|
|
350,000
|
|
|
|
0
|
|
|
|
0%
|
|
DATHNA Partners LLC
|
|
|
30,000
|
|
|
|
*
|
|
|
|
30,000
|
|
|
|
0
|
|
|
|
0%
|
|
TOTAL
|
|
|
34,808,286
|
|
|
|
|
|
|
|
34,673,202
|
|
|
|
135,084
|
|
|
|
|
|
____________________________
*Less than 1%
1
Based upon 41,810,324 shares
outstanding.
2
Based upon 41,810,324 shares
outstanding after the offering.
3
Includes 4,200 held in a brokerage
account by Stephen Funk, the Managing Member.
4
Mr. Dibiase served as our
Chief Executive Officer, Interim Financial Officer, and a director until February 28, 2018, at which time he resigned from all
positions but remains in a consultant capacity. He also serves as the Chief Executive Officer, Interim Chief Financial Officer,
and director of OXYS, our operating subsidiary.
5
Mr. Mattia is a FINRA-registered
broker-dealer and is also affiliated with NYPPEX, LLC, a FINRA-registered brokerage firm. Due to Mr. Mattia’s license as
a FINRA-registered broker-dealer, he is a statutory underwriter.
6
Mr. Hughes is affiliated with
Issuer Direct, the transfer agent of the Company.
7
Mr. Mitta serves as a director
of the Company. He also serves as a director of OXYS.
Each of the selling stockholders received
his, her, or its shares either in the reverse acquisition transaction which closed on July 28, 2017, pursuant to a Consulting Agreement
dated October 1, 2017, or pursuant to a Consulting Agreement dated effective December 1, 2017.
The number and percentage of shares beneficially
owned is determined in accordance with Rule 13d-3 of the Exchange Act and the information is not necessarily indicative of beneficial
ownership for any other purpose. Under such rule, beneficial ownership includes any shares as to which the selling shareholder
has sole or shared voting power or investment power and also any shares, which the selling shareholder has the right to acquire
within 60 days. Except for as noted above, none of our selling stockholders is a broker-dealer or an affiliate of a broker-dealer.
DESCRIPTION OF SECURITIES
Authorized Capital Stock
We have 190,000,000 shares of Common Stock
authorized with a par value of $0.001. As of the date of this prospectus, we had 41,810,324 common shares issued and outstanding.
Description of our Common Stock
The holders of outstanding common shares
are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such
amounts as the board from time to time may determine. Holders of common stock are entitled to one vote for each share held on all
matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election.
The common shares are not entitled to pre-emptive rights and are not subject to conversion or redemption. Upon liquidation, dissolution
or winding up of the Company, the assets legally available for distribution to stockholders are distributable ratably among the
holders of the common shares after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors.
Each outstanding common share is duly and validly issued, fully paid and non-assessable.
Convertible Securities
As of the date hereof, we do not have any
outstanding convertible securities.
Transfer Agent
Our transfer agent is Issuer Direct whose
address is 1981 E. Murray Holladay Rd #100, Salt Lake City, UT 84117 and its telephone number is (801) 272-9294.
Nevada Anti-Takeover Laws
The Nevada Business Corporation Law contains
a provision governing “Acquisition of Controlling Interest.” This law provides generally that any person or entity
that acquires 20% or more of the outstanding voting shares of a publicly-held Nevada corporation in the secondary public or private
market may be denied voting rights with respect to the acquired shares, unless a majority of the disinterested shareholders of
the corporation elects to restore such voting rights in whole or in part. The control share acquisition act provides that a person
or entity acquires “control shares” whenever it acquires shares that, but for the operation of the control share acquisition
act, would bring its voting power within any of the following three ranges: (1) 20 to 33 1/3%, (2) 33 1/3 to 50%, or (3) more than
50%. A “control share acquisition” is generally defined as the direct or indirect acquisition of either ownership or
voting power associated with issued and outstanding control shares. The shareholders or board of directors of a corporation may
elect to exempt the stock of the corporation from the provisions of the control share acquisition act through adoption of a provision
to that effect in the Articles of Incorporation or Bylaws of the corporation. Our Articles of Incorporation and Bylaws do not exempt
our common stock from the control share acquisition act. The control share acquisition act is applicable only to shares of “Issuing
Corporations” as defined by the act. An Issuing Corporation is a Nevada corporation, which; (1) has 200 or more shareholders,
with at least 100 of such shareholders being both shareholders of record and residents of Nevada; and (2) does business in Nevada
directly or through an affiliated corporation.
At this time, we do not have 100 shareholders
of record resident of Nevada. Therefore, the provisions of the control share acquisition act do not apply to acquisitions of our
shares and will not until such time as these requirements have been met. At such time as they may apply to us, the provisions of
the control share acquisition act may discourage companies or persons interested in acquiring a significant interest in or control
of the company, regardless of whether such acquisition may be in the interest of our shareholders.
The Nevada “Combination with Interested
Stockholders Statute” may also have an effect of delaying or making it more difficult to effect a change in control of the
company. This statute prevents an “interested stockholder” and a resident domestic Nevada corporation from entering
into a “combination,” unless certain conditions are met. The statute defines “combination” to include any
merger or consolidation with an “interested stockholder,” or any sale, lease, exchange, mortgage, pledge, transfer
or other disposition, in one transaction or a series of transactions with an “interested stockholder” having; (1) an
aggregate market value equal to 5% or more of the aggregate market value of the assets of the corporation; (2) an aggregate market
value equal to 5% or more of the aggregate market value of all outstanding shares of the corporation; or (3) representing 10% or
more of the earning power or net income of the corporation. An “interested stockholder” means the beneficial owner
of 10% or more of the voting shares of a resident domestic corporation, or an affiliate or associate thereof. A corporation affected
by the statute may not engage in a “combination” within three years after the interested stockholder acquires its shares
unless the combination or purchase is approved by the board of directors before the interested stockholder acquired such shares.
If approval is not obtained, then after the expiration of the three-year period, the business combination may be consummated with
the approval of the board of directors or a majority of the voting power held by disinterested stockholders, or if the consideration
to be paid by the interested stockholder is at least equal to the highest of: (1) the highest price per share paid by the interested
stockholder within the three years immediately preceding the date of the announcement of the combination or in the transaction
in which he became an interested stockholder, whichever is higher; (2) the market value per common share on the date of announcement
of the combination or the date the interested stockholder acquired the shares, whichever is higher; or (3) if higher for the holders
of preferred stock, the highest liquidation value of the preferred stock. The effect of Nevada’s business combination law
is to potentially discourage parties interested in taking control of the company from doing so if it cannot obtain the approval
of our board of directors.
Currently, we have no Nevada shareholders.
Further, we do not do business in Nevada directly or through an affiliate corporation and we do not intend to do so. Accordingly,
there are no anti-takeover provisions that have the effect of delaying or preventing a change in our control.
Dividend Policy
We have never declared or paid any cash
dividends on our common stock.
PLAN OF DISTRIBUTION
General
The selling stockholders may seek an underwriter,
broker-dealer or selling agent to sell the shares. Except for as disclosed herein, as of the date of this prospectus, no selling
stockholder has entered into any arrangements with any underwriter, broker-dealer or selling agent for the sale of the shares.
The Company has no arrangements, nor has it entered into any agreement with any underwriters, broker-dealer or selling agents for
the sale of the shares.
The selling stockholders and any underwriters,
broker-dealers or agents who participate in the sale or distribution of the shares may be deemed to be “underwriters”
within the meaning of the Securities Act. As a result, any profits on the sale of the shares by the selling stockholders and any
discounts, commissions or agent’s commissions or concessions received by any such broker-dealer or agents may be deemed to
be underwriting discounts and commissions under the Securities Act. If any selling stockholder is deemed to be an “underwriter”
within the meaning of Section 2(11) of the Securities Act, it will be subject to prospectus delivery requirements of the Securities
Act. Underwriters are subject to certain statutory liabilities, including, but not limited to, Sections 11, 12 and 17 of the Securities
Act.
The selling stockholders are not obligated
to sell any or all of the shares under this prospectus. Further, they are may transfer, devise or gift the shares by other means
not described in this prospectus. In addition, any shares covered by this prospectus that qualify for sale under Rule 144 or Rule
144A of the Securities Act may be sold under Rule 144 or Rule 144A in certain instances, rather than under this prospectus.
The shares covered by this prospectus may
also be sold to non-U.S. persons outside the U.S. in accordance with Regulation S under the Securities Act rather than under this
prospectus. The shares may be sold in some states only through registered or licensed brokers or dealers. In addition, in some
states the shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification
is available and complied with. If any of the shares offered for resale pursuant to this prospectus are transferred other than
pursuant to a sale under this prospectus, the subsequent holders could not use this prospectus until a post-effective amendment
to the registration statement of which this prospectus is a part or a prospectus supplement is filed naming such holders.
The selling stockholders and any other
person participating in the sale of the shares may be subject to the Exchange Act. The Exchange Act rules include, without limitation,
Regulation M, which may limit the timing of purchases and sales of any of the shares by the selling stockholders and any other
such person. In addition, Regulation M may restrict the ability of any person engaged in the distribution of the common stock to
engage in market-making activities with respect to the particular shares being distributed. This may affect the marketability of
the shares and the ability of any person or entity to engage in market-making activities with respect to the shares.
The Company intends to maintain the currency
and accuracy of this prospectus for a period of up to two years, unless earlier completely sold, pursuant to Rule 415 of the General
Rules and Regulations of the Securities and Exchange Commission.
Resales of the Shares under State
Securities Laws
The National Securities Market Improvement
Act of 1996 (“
NSMIA
”) limits the authority of states to impose restrictions upon resales of securities made
pursuant to Sections 4(a)(1) and 4(a)(3) of the Securities Act of companies which file reports under Sections 13 or 15(d) of the
Exchange Act. Resales of the shares in the secondary market will be made pursuant to Section 4(a)(1) of the Securities Act (sales
other than by an issuer, underwriter or broker).
LEGAL MATTERS
The validity of the shares of common stock
offered under this prospectus is being passed upon for us by Business Legal Advisors, LLC.
EXPERTS
Our financial statements for the years
ended December 31, 2017 and 2018, were audited by Haynie & Company, and are included in reliance upon such reports given upon
the authority of Haynie & Company , as experts in accounting and auditing.”
ADDITIONAL INFORMATION
We have filed a registration statement
on Form S-1 under the Securities Act (SEC File No. 333-_________) relating to the shares of common stock being offered by this
prospectus, and reference is made to such registration statement. This prospectus constitutes the prospectus of IIOT-OXYS, Inc.,
filed as part of the registration statement, and it does not contain all information in the registration statement, as certain
portions have been omitted in accordance with the rules and regulations of the SEC.
Upon the effective date of the registration
statement of which this prospectus is a part, we will be required to file reports and other documents with the SEC. We do not presently
intend to voluntarily furnish you with a copy of our annual report. You may read and copy any materials we file with the SEC at
the public reference room of the SEC at 100 F Street, NE., Washington, DC 20549, between the hours of 10:00 a.m. and 3:00 p.m.,
except federal holidays and official closings, at the Public Reference Room. You may obtain information on the operation of the
Public Reference Room by calling the SEC at 1-800-SEC-0330. Our SEC filings are also available to you on the Internet website for
the SEC at http://www.sec.gov.
INDEX TO FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of
IIoT-OXYS, Inc.
Opinion on the Financial
Statements
We have audited the accompanying
consolidated balance sheets of IIoT-OXYS, Inc. (the Company) as of December 31, 2018 and 2017, and the related consolidated statements
of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December
31, 2018, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results
of its operations and its cash flows for each of the years in the two-year period ended December 31, 2018, in conformity with accounting
principles generally accepted in the United States of America.
Consideration of the Company’s
Ability to Continue as a Going Concern
The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2 to
the financial statements, the Company has incurred net losses since inception and has negative cash flows from operations. These
factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard
to these matters are also described in Note 2 to the financial statements. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements
are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of
our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of
expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express
no such opinion.
Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable
basis for our opinion.
Haynie & Company
Salt Lake City,
Utah
April 16, 2019
We have served as the Company’s
auditor since 2018.
|
|
IIOT-OXYS, Inc. and Subsidiaries
Consolidated Balance Sheets
As of December 31, 2018 and December 31, 2017
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
Assets
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents
|
|
$
|
39,226
|
|
|
$
|
60,863
|
|
Cash - Escrow
|
|
|
–
|
|
|
|
1,782
|
|
Accounts Receivable, net
|
|
|
33,000
|
|
|
|
39,800
|
|
Prepaid Expense
|
|
|
4,452
|
|
|
|
14,778
|
|
Inventory
|
|
|
317
|
|
|
|
–
|
|
Total Current Assets
|
|
|
76,995
|
|
|
|
117,223
|
|
Intangible Assets, net
|
|
|
446,992
|
|
|
|
–
|
|
Other Assets
|
|
|
–
|
|
|
|
1,000
|
|
Total Assets
|
|
$
|
523,987
|
|
|
$
|
118,223
|
|
Liabilities and Stockholders' (Deficit) Equity
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
$
|
377,962
|
|
|
$
|
38,560
|
|
Accrued Liabilities
|
|
|
449,729
|
|
|
|
–
|
|
Total Current Liabilities
|
|
|
827,691
|
|
|
|
38,560
|
|
Note Payable, net
|
|
|
234,932
|
|
|
|
–
|
|
Due to Stockholder
|
|
|
1,000
|
|
|
|
1,000
|
|
Total Liabilities
|
|
|
1,063,623
|
|
|
|
39,560
|
|
Commitments and Contingencies (note 8)
|
|
|
|
|
|
|
|
|
Stockholders' (Deficit) Equity
|
|
|
|
|
|
|
|
|
Preferred stock $0.001 par value, 10,000,000 shares authorized; 0 issued and outstanding
|
|
|
–
|
|
|
|
–
|
|
Common stock $0.001 par value, 190,000,000 shares authorized; 40,633,327 and 38,983,327 shares issued and outstanding, respectively
|
|
|
40,633
|
|
|
|
38,983
|
|
Additional Paid-in Capital
|
|
|
2,572,751
|
|
|
|
1,579,401
|
|
Accumulated Deficit
|
|
|
(3,153,020
|
)
|
|
|
(1,539,721
|
)
|
Total Stockholders' (Deficit) Equity
|
|
|
(539,636
|
)
|
|
|
78,663
|
|
Total Liabilities and Stockholders' (Deficit) Equity
|
|
$
|
523,987
|
|
|
$
|
118,223
|
|
See accompanying notes to audited consolidated financial statements.
IIOT-OXYS, Inc. and Subsidiaries
Consolidated Statements of Operations
For the Years Ended December 31, 2018 and 2017
|
|
Year Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Revenues
|
|
|
|
|
|
|
|
|
Sales
|
|
$
|
224,643
|
|
|
$
|
39,800
|
|
Cost of Sales
|
|
|
135,008
|
|
|
|
47,887
|
|
Gross Profit
|
|
|
89,635
|
|
|
|
(8,087
|
)
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
Demo Parts
|
|
|
3,217
|
|
|
|
34,393
|
|
Bank Service Charges
|
|
|
718
|
|
|
|
648
|
|
Office Expenses
|
|
|
38,279
|
|
|
|
17,090
|
|
Organization Costs
|
|
|
22,930
|
|
|
|
23,808
|
|
Insurance
|
|
|
24,518
|
|
|
|
8,372
|
|
Professional
|
|
|
1,152,798
|
|
|
|
1,416,527
|
|
Travel
|
|
|
15,645
|
|
|
|
22,158
|
|
Patent License Fee
|
|
|
106,065
|
|
|
|
–
|
|
Amortization of Intangible Assets
|
|
|
48,220
|
|
|
|
–
|
|
Total Expenses
|
|
|
1,412,390
|
|
|
|
1,522,996
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expenses)
|
|
|
|
|
|
|
|
|
Interest Expense
|
|
|
(291,729
|
)
|
|
|
(12
|
)
|
Miscellaneous Income
|
|
|
1,185
|
|
|
|
–
|
|
Total Other Income (Expense)
|
|
|
(290,544
|
)
|
|
|
(12
|
)
|
|
|
|
|
|
|
|
|
|
Net Loss Before Income Taxes
|
|
|
(1,613,299
|
)
|
|
|
(1,531,095
|
)
|
|
|
|
|
|
|
|
|
|
Income Tax Benefit
|
|
|
–
|
|
|
|
–
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(1,613,299
|
)
|
|
$
|
(1,531,095
|
)
|
|
|
|
|
|
|
|
|
|
Loss per Common Share
|
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
|
|
|
|
|
|
|
|
Weighted Average Number of Shares Outstanding - Basic and Diluted
|
|
|
40,601,683
|
|
|
|
36,241,821
|
|
See accompanying notes to audited consolidated financial statements.
IIOT-OXYS, Inc. and Subsidiaries
Consolidated Statements of Stockholders' Equity (Deficit)
For the Years Ended December 31, 2018 and 2017
|
|
Common Stock
|
|
|
Additional
Paid-In
|
|
|
Accumulated
|
|
|
Total Stockholders' Equity
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
(Deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2016
|
|
|
33,197,769
|
|
|
$
|
9,957
|
|
|
$
|
542,204
|
|
|
$
|
(8,626
|
)
|
|
$
|
543,535
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $0.10 per share
|
|
|
1,489,474
|
|
|
|
447
|
|
|
|
141,052
|
|
|
|
–
|
|
|
|
141,499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $1.15 to $1.90 per share
|
|
|
530,000
|
|
|
|
530
|
|
|
|
994,970
|
|
|
|
–
|
|
|
|
995,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To reflect effect of acquisition (reverse merger/recapitalization)
|
|
|
3,766,084
|
|
|
|
28,049
|
|
|
|
(98,825
|
)
|
|
|
–
|
|
|
|
(70,776
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
(1,531,095
|
)
|
|
|
(1,531,095
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2017
|
|
|
38,983,327
|
|
|
|
38,983
|
|
|
|
1,579,401
|
|
|
|
(1,539,721
|
)
|
|
|
78,663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of HereLab
|
|
|
1,650,000
|
|
|
|
1,650
|
|
|
|
493,350
|
|
|
|
–
|
|
|
|
495,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To reflect beneficial conversion feature discount on note payable
|
|
|
–
|
|
|
|
–
|
|
|
|
500,000
|
|
|
|
–
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
(1,613,299
|
)
|
|
|
(1,613,299
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2018
|
|
|
40,633,327
|
|
|
$
|
40,633
|
|
|
$
|
2,572,751
|
|
|
$
|
(3,153,020
|
)
|
|
$
|
(539,636
|
)
|
See accompanying notes to audited consolidated financial statements.
IIOT-OXYS, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the Years ended
December 31, 2018 and 2017
|
|
Year ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Cash Flows from Operating Activities:
|
|
|
|
|
|
|
|
|
Net Loss
|
|
$
|
(1,613,299
|
)
|
|
$
|
(1,531,095
|
)
|
Adjustments to reconcile net loss to net cash (used) by operating activities:
|
|
|
|
|
|
|
|
|
Stock Based Compensation
|
|
|
449,729
|
|
|
|
995,500
|
|
Acquisition of Net Assets
|
|
|
(212
|
)
|
|
|
–
|
|
Amortization of Discount on Note Payable
|
|
|
234,932
|
|
|
|
–
|
|
Amortization of Intangible Assets
|
|
|
48,220
|
|
|
|
–
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
(Increase) Decrease in:
|
|
|
|
|
|
|
|
|
Accounts Receivable
|
|
|
6,800
|
|
|
|
(39,800
|
)
|
Inventory
|
|
|
(317
|
)
|
|
|
10,035
|
|
Prepaid Expense
|
|
|
10,326
|
|
|
|
(14,778
|
)
|
Escrow
|
|
|
1,782
|
|
|
|
50,877
|
|
Licensing Agreement
|
|
|
1,000
|
|
|
|
–
|
|
Increase (Decrease) in:
|
|
|
|
|
|
|
|
|
Accounts Payable
|
|
|
339,402
|
|
|
|
38,560
|
|
Net Cash Used by Operating Activities
|
|
|
(521,637
|
)
|
|
|
(490,701
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities:
|
|
|
|
|
|
|
|
|
Cash Paid in Conjunction with Licensing Agreement
|
|
|
–
|
|
|
|
(1,000
|
)
|
Net Cash Used by Investing Activities
|
|
|
–
|
|
|
|
(1,000
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities:
|
|
|
|
|
|
|
|
|
Cash Received from Convertible Note Payable
|
|
|
500,000
|
|
|
|
–
|
|
Cash Received from Issuance of Common Stock
|
|
|
–
|
|
|
|
179,953
|
|
Cash Paid for Offering Cost
|
|
|
–
|
|
|
|
(109,230
|
)
|
Net Cash Provided by Financing Activities
|
|
|
500,000
|
|
|
|
70,723
|
|
|
|
|
|
|
|
|
|
|
Net Decrease in Cash and Cash Equivalents
|
|
|
(21,637
|
)
|
|
|
(420,978
|
)
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents at Beginning of Period
|
|
|
60,863
|
|
|
|
481,841
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents at End of Period
|
|
$
|
39,226
|
|
|
$
|
60,863
|
|
|
|
|
|
|
|
|
|
|
Supplemental Information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid during the period
|
|
$
|
56,797
|
|
|
$
|
12
|
|
Taxes paid during the period
|
|
$
|
–
|
|
|
$
|
–
|
|
|
|
|
-
|
|
|
|
-
|
|
Supplemental Schedule of Non-Cash Investing and Financing Activities:
|
|
|
|
|
|
|
|
|
Fair value of shares issued in acquisition of subsidiary
|
|
$
|
495,000
|
|
|
$
|
–
|
|
Fair value of intangible assets received in acquisition of subsidiary
|
|
$
|
495,212
|
|
|
$
|
–
|
|
See accompanying notes to audited consolidated financial statements.
IIOT-OXYS, Inc. and Subsidiaries
Notes to Audited Consolidated Financial
Statements
December 31, 2018
1. NATURE OF OPERATIONS
On July 28, 2017, IIOT-OXYS, Inc., a Nevada
corporation (the “
Company
”) (previously known as Gotham Capital Holdings, Inc.), executed and closed (the “
Closing
”)
the Securities Exchange Agreement dated effective March 16, 2017, between the Company, OXYS Corporation, a Nevada corporation (“
OXYS
”),
and the shareholders of OXYS and changed its name to “IIOT-OXYS, Inc.” As a result of the closing, the Company issued
an aggregate of 34,687,244 shares on a pro rata basis to the shareholders of OXYS, and OXYS became a wholly owned subsidiary of
the Company. In addition, the Company cancelled 1,500,000 outstanding shares held by principal shareholders of the Company, which
resulted in a total of 38,453,328 shares issued and outstanding upon completion of the Closing.
On December 14, 2017, the Company entered
into a Securities Exchange Agreement dated December 14, 2017, between the Company, OXYS, and HereLab, Inc., a Delaware corporation
(“
HereLab
”), and the shareholders of HereLab. Upon completion of the closing of the Exchange Agreement, on January
11, 2018, the Company issued an aggregate of 1,650,000 shares of its common stock on a pro rata basis to the two shareholders of
HereLab and HereLab became a wholly-owned subsidiary of the Company.
OXYS Corporation was incorporated on August
4, 2016 in Nevada. It maintains its principal office in Massachusetts at 705 Cambridge St., Cambridge, MA 02142.
The Company was only recently formed and
is currently devoting substantially all its efforts in identifying, developing and marketing engineered products, software and
services for applications in the Industrial Internet which involves collecting and processing data collected from a wide variety
of industrial systems and machines.
2. SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES
Basis of Presentation
The Company's financial statements are
prepared on the accrual method of accounting. The accounting and reporting policies of the Company conform with generally accepted
accounting principles (“
GAAP
”).
Principles of Consolidation
The consolidated financial statements for
December 31, 2018 include the accounts of IIOT-OXYS, Inc., OXYS Corporation, and HereLab, Inc. as of the closing date of the acquisition
agreement dated January 11, 2018. All significant intercompany balances and transactions have been eliminated.
The consolidated financial statements
for December 31, 2017 include the accounts of IIOT-OXYS, Inc. and OXYS Corporation as of the closing of the acquisition agreement
dated July 28, 2017. All significant intercompany balances and transactions have been eliminated.
Accounts Receivable and Allowance for
Doubtful Accounts
Trade accounts receivable are carried at
original invoice amount less an estimate made for doubtful accounts. The Company determines the allowance for doubtful accounts
by identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts.
Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written
off are recorded as income when received. The allowance for doubtful accounts at December 31, 2018 and 2017 was $0.
Revenue Recognition
The Company’s revenue is derived
primarily from providing services under contractual agreements. The Company recognizes revenue in accordance with ASC Topic No.
606, Revenue from Contracts with Customers (“ASC 606”) which was adopted on January 1, 2018, using the modified retrospective
method, which was elected to apply to all active contracts as of the adoption date. Application of the modified retrospective method
did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as
the Company's method of recognizing revenue under ASC 606 yielded similar results to the method utilized immediately prior to adoption.
Accordingly, there was no effect to each financial statement line item as a result of applying the new revenue standard.
According to ASC 606, the Company recognizes
revenue based on the following criteria:
|
·
|
Identification of a contract or contracts, with a customer.
|
|
·
|
Identification of the performance obligations in the contract.
|
|
·
|
Determination of contract price.
|
|
·
|
Allocation of transaction price to the performance obligation.
|
|
·
|
Recognition of revenue when, or as, performance obligation is satisfied.
|
We used a practical expedient available
under ASC 606-10-65-1(f)4 that permits us to consider the aggregate effect of all contract modifications that occurred before the
beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price,
and allocating the transaction price to the satisfied and unsatisfied performance obligations
.
We have elected to treat shipping and handling
activities as cost of sales. Additionally, we have elected to record revenue net of sales and other similar taxes.
Reclassification
Certain amounts in prior-period financial
statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements.
Use of Estimates
Management uses estimates and assumptions
in preparing these financial statements in accordance with generally accepted accounting principles. These estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported revenues and expenses during the reporting period. Actual results could vary from the estimates that
were used.
Fair Value of Financial Instruments
Fair Value of Financial Instruments - The
Company accounts for fair value measurements in accordance with accounting standard ASC 820-10-50, Fair Value Measurements. This
guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances
disclosure requirements for fair value measures. The three levels are defined as follows:
Level 1 inputs to the valuation methodology
are quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 inputs to the valuation methodology
include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability,
either directly or indirectly, for substantially the full term of the financial instrument.
Level 3 inputs to valuation methodology
are unobservable and significant to the fair measurement.
The fair value of certain of the Company’s
financial instruments including cash and cash equivalents approximate their carrying amounts because of the short-term maturity
of these instruments.
Income Taxes
The Company accounts for income taxes in
accordance with FASB ASC 740, Income Taxes, which requires the recognition of deferred income taxes for differences between the
basis of assets and liabilities for financial statement and income tax purposes. Deferred taxes are recognized for operating losses
that are available to offset future taxable income. Valuation allowances are established to reduce deferred tax assets to the amount
expected to be realized.
The Company adopted the provisions of FASB
ASC 740-10-25, which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions
taken or expected to be taken in income tax returns. FASB ASC 740-10-25 also provides guidance on de-recognition of income tax
assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and
penalties associated with tax positions. The Company's tax returns are subject to tax examinations by U.S. federal and state authorities
until respective statute of limitation. Currently, the tax years ended December 31, 2018 and 2017 are open and subject to examination
by taxing authorities. However, the Company is not currently under audit nor has the Company been contacted by any of the taxing
authorities. The Company does not have any accruals for uncertain tax positions at December 31, 2018 and 2017. It is not anticipated
that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.
Cash and Cash Equivalents
For purposes of the statement of cash flows,
the Company considers all unrestricted highly liquid investments with an original maturity of three months or less to be cash equivalents.
Concentration of Risk
Financial instruments that potentially
expose the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized.
The Company’s policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit
the amount of credit exposure. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC), up
to $250,000. At December 31, 2018 and 2017, the Company had approximately no amounts in excess of the FDIC insurance limit.
Inventory
Inventory consists primarily of demo equipment
and is recorded at the lower of cost (first-in, first out method) or market.
Long-Lived Assets
The Company regularly reviews the carrying
value and estimated lives of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments
to the carrying value or estimated useful lives. The determinants used for this evaluation include management’s estimate
of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the
strategic significance of the assets to the Company’s business objectives.
Definite-lived intangible assets are amortized
on a straight-line basis over the estimated periods benefited and are reviewed when appropriate for possible impairment.
Convertible Debt
Convertible debt is accounted for under
FASB ASC 470, Debt – Debt with Conversion and Other Options. The Company records a beneficial conversion feature (“
BCF
”)
related to the issuance of convertible debt that has conversion features at fixed or adjustable rates that are in-the-money when
issued and records the relative fair value of any warrants issued with those instruments. The BCF for the convertible instruments
is recognized and measured by allocating a portion of the proceeds to the warrants and as a reduction to the carrying amount of
the convertible instrument equal to the intrinsic value of the conversion features, both of which are credited to additional paid-in
capital. The Company calculates the fair value of warrants issued with the convertible instruments using the Black-Scholes
valuation method, using the same assumptions used for valuing stock options.
Under these guidelines, the registrant
allocates the value of the proceeds received from a convertible debt transaction between the conversion feature and any other detachable
instruments (such as warrants) on a relative fair value basis. The allocated fair value of the BCF and warrants are recorded
as a debt discount and is accreted over the expected term of the convertible debt as interest expense.
The Company accounts for modifications
of its embedded conversion features in accordance with the ASC which requires the modification of a convertible debt instrument
that changes the fair value of an embedded conversion feature and the subsequent recognition of interest expense or the associated
debt instrument when the modification does not result in a debt extinguishment.
Basic and Diluted Net Loss Per Common
Share
The Company computes basic and diluted
net loss attributable to common stockholders for the period under ASC 260-10, Earnings Per Share, which requires a dual presentation
of basic and diluted earnings or loss per share. Basic net loss per share is computed by dividing net loss attributable to common
stockholders for the period by the weighted-average number of common shares, including potential dilutive shares of common stock
assuming the dilutive effect of potential dilutive securities. Diluted earnings per share represent basic earnings per share adjusted
to include the potentially dilutive effect of stock options, convertible preferred stock and common stock warrants. For periods
in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, because
their impact would be anti-dilutive to the calculation of net loss per common share. Diluted net loss per common share is the
same as basic net loss per common share for the years ended December 31, 2018 and 2017. For the year ended December 31, 2018 there
were 384,615 anti-dilutive outstanding stock warrants. For the year ended December 31, 2017 there were no amounts of anti-dilutive
security instruments outstanding.
Going Concern
The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the
Company was only recently formed, has incurred continuing operating losses and has an accumulated deficit of $3,153,020 and $1,539,721
at December 31, 2018 and 2017, respectively. These factors raise substantial doubt about the ability of the Company to continue
as a going concern.
Management believes that it will be able
to achieve a satisfactory level of liquidity to meet the Company’s obligations for the next 12 months by generating cash
through additional borrowings and/or issuances of equity securities, as needed. However, there can be no assurance that the Company
will be able to generate sufficient liquidity to maintain its operations. The financial statements do not include any adjustments
that might result from the outcome of these uncertainties.
3. RECENT ACCOUNTING PRONOUNCEMENTS
ASU 2016-02
In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842). The new standard establishes a right-of-use ("
ROU
") model that requires a lessee to record
a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will
be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within
those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital
and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial
statements, with certain practical expedients available. On January 1, 2019, the Company adopted ASU 2016-02. The Company is not
a lessee of a lease longer than 12 months nor has the Company been a lessee of a lease longer than 12 months in prior periods therefore
there is no impact of the adoption of this standard.
ASU 2017-11
In July 2017, the FASB issued ASU No. 2017-11,
Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments
in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features)
with down round features.
When determining whether certain financial
instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification
when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure
requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion
option) no longer would be accounted for as a derivative liability at fair value. For freestanding equity classified financial
instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the
effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available
to common shareholders in basic EPS.
For public business entities, the amendments
in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December
15, 2018. Early adoption is permitted including adoption in an interim period. On January 1, 2018, the Company early adopted ASU
2017-11. See Note 11 for the effect early implementation had on 384,615 warrants issued in conjunction with the $500,000 convertible
note issuance. Since the Company did not have any of these type of instruments in prior periods there is no effect of early implementation
on prior periods.
ASU 2018-07
In June 2018, the FASB issued ASU 2018-07,
Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, which aligned
certain aspects of share-based payments accounting between employees and nonemployees. Specifically, nonemployee share-based payment
awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated
to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right
to benefit from the instruments have been satisfied and an entity considers the probability of satisfying performance conditions
when nonemployee share-based payment awards contain such conditions. ASU 2018-17 is effective for the Company beginning the first
quarter of 2019. The new standard will not have a significant impact on the Company’s financial statements or disclosures.
Other accounting standards that have been
issued or proposed by FASB do not require adoption until a future date are not expected to have a material impact on the consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact
on or are unrelated to its financial condition, results of operations, cash flows or disclosures.
4. BUSINESS COMBINATION
On December 14, 2017, the Company entered
into a Securities Exchange Agreement dated December 14, 2017, between the Company, OXYS, and HereLab, Inc., a Delaware corporation
(“
HereLab
”), and the shareholders of HereLab. Upon completion of the closing of the Exchange Agreement, on January
11, 2018, the Company issued an aggregate of 1,650,000 shares of its common stock on a pro rata basis to the two shareholders of
HereLab and HereLab became a wholly-owned subsidiary of the Company.
The combination was accounted for under
the acquisition method of accounting for business combinations and OXYS was considered to be the acquiring company. Under the acquisition
method of accounting, total consideration exchanged included $495,000 of OXYS common stock.
The purchase price allocation to assets
and liabilities assumed in the transaction was:
Current assets
|
|
$
|
3,119
|
|
Current liabilities
|
|
|
(3,331
|
)
|
Field tests
|
|
|
302,079
|
|
Sensor integrations
|
|
|
128,755
|
|
Board designs
|
|
|
64,378
|
|
Net assets acquired
|
|
|
495,000
|
|
Total consideration
|
|
$
|
495,000
|
|
Under the acquisition method of accounting
identifiable intangible assets were recorded based on their estimated fair values as of the effective time of the acquisition.
Cash, accounts receivable, and income tax payable were valued at their respective carrying amounts, which management believes approximates
their fair values.
Acquired intangible assets included specific
board designs, sensor integrations, and related field tests are definite lived assets and are being amortized over a 10-year useful
life.
The following table provides unaudited
proforma results, prepared in accordance with ASC 805, for the year ended December 31, 2017, as if HereLab had been acquired at
the beginning of the period.
|
|
For the year ended
|
|
|
|
December 31, 2017
|
|
Gross profit
|
|
$
|
2,368
|
|
Net loss
|
|
$
|
(499,775
|
)
|
Net loss per share, basic and diluted
|
|
$
|
(0.02
|
)
|
The unaudited proforma results include
adjustments to eliminate the sales and expenses incurred between the Company and HereLab during the period.
The unaudited proforma condensed results
do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other
savings or expenses that may be associated with the acquisition.
Unaudited proforma amounts are not necessarily
indicative of future results.
5. FAIR VALUE MEASUREMENTS
ASC 820 "Fair Value Measurements,"
defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances
disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a
fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable,
that may be used to measure fair value which are the following:
|
·
|
|
Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets.
|
|
·
|
|
Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable.
|
|
·
|
|
Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions.
|
The following tables set forth the fair
value of the Company’s consolidated financial instruments that were measured at fair value on the effective date of the respective
agreements as of December 31, 2018 and 2017:
|
|
December 31, 2018
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Shares issued in acquisition of HereLab
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
495,000
|
|
|
$
|
495,000
|
|
Accrued share compensation
|
|
|
32,500
|
|
|
|
–
|
|
|
|
417,229
|
|
|
|
449,729
|
|
Total fair value
|
|
$
|
32,500
|
|
|
$
|
–
|
|
|
$
|
912,229
|
|
|
$
|
944,729
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2017
|
|
|
|
|
Level 1
|
|
|
|
Level 2
|
|
|
|
Level 3
|
|
|
|
Total
|
|
Shares issued in acquisition of HereLab
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
Accrued share compensation
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
|
|
–
|
|
Total fair value
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
|
$
|
–
|
|
The shares of common stock associated
with the Level 1 accrued share compensation liability are shares issued to a consultant in exchange for work provided during the
period, but not yet issued, related to a settlement agreement discussed in Note 8. The fair value was calculated based on market
prices for the shares in an active market on the effective date of the agreement.
The shares of common stock associated with
the Level 3 accrued share compensation liability are the unvested shares earned on a pro-rata basis as of December 31, 2018 related
to the five consulting agreements discussed in Note 8. The fair value was calculated based on comparable adjusted amounts the Company
was raising funds at multiplied by the total shares agreed upon on the effective date of the respective agreements. The share compensation
amount is amortized over the life of the agreements.
The shares of common stock associated with
the Level 3 shares issued in the acquisition of Herelab were valued based on comparable adjusted amounts the Company was raising
funds at on the effective date of the agreement.
6. INCOME TAXES
The Company accounts for income taxes in
accordance with ASC Topic No. 740. This standard requires the Company to provide a net deferred tax asset or liability equal to
the expected future tax benefit or expense of temporary reporting differences between book and tax accounting methods and any available
operating loss or tax credit carryforwards. Income tax returns open for examination by the Internal Revenue Service consist of
tax years ended December 31, 2018 and 2017.
The Company has available at December
31, 2018, unused operating loss carryforwards of approximately $3,153,020 which may be applied against future taxable income and
which expire in various years through 2036. However, if certain substantial changes in the Company’s ownership should occur,
there could be an annual limitation on the amount of net operating loss carryforward which can be utilized. The amount of and
ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon
the tax laws in effect, the future earnings of the Company and other future events, the effects of which cannot be determined.
Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance
equal to the tax effect of the loss carryforwards and other temporary differences of approximately $815,056 and $398,018 at December
31, 2018 and 2017, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards. The change
in the valuation allowance is approximately $417,038 and $395,788 for the years ended December 31, 2018 and 2017, respectively.
Deferred tax assets are comprised of the
following:
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
NOL carryover
|
|
$
|
815,056
|
|
|
$
|
398,018
|
|
Valuation allowance
|
|
|
(815,056
|
)
|
|
|
(398,018
|
)
|
Net deferred tax asset
|
|
$
|
–
|
|
|
$
|
–
|
|
The reconciliation of the provisions for
income taxes computed at the U.S. federal statutory tax rate (21%) to the Company’s effective tax rate for the periods ended
December 31, 2018 and 2017 is as follows:
|
|
December 31,
2018
|
|
|
December 31,
2017
|
|
Book loss
|
|
$
|
338,793
|
|
|
$
|
321,530
|
|
State taxes
|
|
|
78,245
|
|
|
|
74,258
|
|
Change in valuation allowance
|
|
|
(417,038
|
)
|
|
|
(395,788
|
)
|
Provision for income taxes
|
|
$
|
–
|
|
|
$
|
–
|
|
7. INTANGIBLE ASSETS, NET
Intangible assets, net of amortization
at December 31, 2018 and 2017 amounted to $446,992 and $0, respectively.
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
Field tests
|
|
$
|
302,079
|
|
|
$
|
–
|
|
Accumulated field tests amortization
|
|
|
(29,414
|
)
|
|
|
–
|
|
Field tests, net
|
|
|
272,665
|
|
|
|
–
|
|
Sensor integrations
|
|
|
128,755
|
|
|
|
–
|
|
Accumulated sensor integrations amortization
|
|
|
(12,537
|
)
|
|
|
–
|
|
Sensor integrations, net
|
|
|
116,218
|
|
|
|
–
|
|
Board designs
|
|
|
64,378
|
|
|
|
–
|
|
Accumulated board designs amortization
|
|
|
(6,269
|
)
|
|
|
–
|
|
Board designs, net
|
|
|
58,109
|
|
|
|
–
|
|
Total intangible assets, net
|
|
$
|
446,992
|
|
|
$
|
–
|
|
At December 31, 2018 the Company determined
that none of its intangible assets were impaired. Amortizable intangible assets are amortized using the straight-line method over
their estimated useful lives ten years. Amortization expense of finite-lived intangibles was $48,220 for the year ended December
31, 2018.
The following table summarizes the Company’s
estimated future amortization expense of intangible assets with finite lives as of December 31, 2018:
|
|
Amortization expense
|
|
2019
|
|
|
49,500
|
|
2020
|
|
|
49,500
|
|
2021
|
|
|
49,500
|
|
2022
|
|
|
49,500
|
|
2023
|
|
|
49,500
|
|
Thereafter
|
|
|
199,492
|
|
|
|
|
446,992
|
|
8. COMMITMENTS AND CONTINGENCIES
The Company entered into a lease agreement
on March 12, 2019 which began on January 1, 2019 and will terminate on June 30, 2019. The Company shall pay the landlord monthly
installments of $2,000 for a total lease payment of $12,000 in 2019.
On March 7, 2019, the Board of Directors
of the Company approved the Settlement Agreement dated effective October 5, 2018 with a consultant pursuant to which the Company
agreed to issue to the consultant 65,000 shares of the Company’s common stock in exchange for payment, in full, for consulting
services provided by the consultant to the Company in 2018.
The Company entered into consulting agreements
with one director, three executive officers, and one engineer of the Company throughout the period which include commitments to
issue shares of the Company’s common stock from the Company’s Stock Incentive Plan.
According to the agreement with the director,
the shares vest annually over three years at the end of the fiscal year. According to the agreements with the executive officers
and engineer, the shares vest annually over three years on the anniversary of each agreement.
In the event that the agreement is terminated
by either party pursuant to the terms of the agreement, all unvested shares which have been earned shall vest on a pro-rata basis
as of the effective date of the termination of the agreement and all unearned, unvested shares shall be terminated.
The consulting agreement with the director
was terminated upon the resignation of the director on September 20, 2018 and, pursuant to a Settlement Agreement, 104,673 earned
shares were vested. According to the remaining four agreements, shares are scheduled to vest over the next three years according
to the following schedule: 1,319,000 shares of common stock in 2019, 2,470,000 shares of common stock in 2020, and 3,680,000 shares
of common stock in 2021.
The value of the shares was assigned at
fair market value on the effective date of the agreement and the pro-rata number of shares earned was calculated and amortized
at the end of each reporting period as discussed in Note 5. As of December 31, 2018, no shares of common stock have been issued
to these individuals and the Company has accrued $417,229 in shares payable in conjunction with these agreements. A summary of
these agreements is as follows.
On March 11, 2019, the Company’s
Board of Directors (with Mr. Emmons abstaining) approved the Consulting Agreement dated effective June 4, 2018 with its CEO. The
term of the agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement
and is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by the CEO pursuant
to the agreement are those customary for the positions in which the CEO is serving. The CEO shall receive a monthly fee of $15,000
which accrues unless converted into shares of common stock of the Company at a conversion rate specified in the agreement. Until
the Company closes a minimum $500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital raise, $5,000
of the monthly fee will be paid to the CEO in cash and the remainder will continue to accrue. Upon the closing of a capital raise
of at least $2,000,000, the entire monthly fee will be paid to the CEO in cash and all accrued and unpaid monthly fees will be
paid by the Company within one year of the closing of such a capital raise. As of the effective date, the Company shall issue to
the CEO an aggregate of 3,060,000 shares of the Company’s common stock which vest as follows:
1.
560,000 shares on the first-year anniversary of the effective date;
2.
1,000,000 shares on the second-year anniversary of the effective date; and
3.
1,500,000 shares on the third-year anniversary of the effective date.
The shares are issued under the 2019 Stock
Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change
of Control (as defined in the agreement) or the listing of the Company’s common stock on a senior exchange.
On March 11, 2019, the Company’s
Board of Directors approved the Consulting Agreement dated effective October 1, 2018 with its COO. The term of the agreement is
for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable
for one-year terms upon the consent of the parties. The services to be provided by the COO pursuant to the agreement are those
customary for the position in which the COO is serving. The COO shall receive a monthly fee of $12,750 which accrues unless converted
into shares of common stock of the Company at a conversion rate specified in the agreement. Until the Company closes a minimum
$500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital raise, $4,250 of the monthly fee will be
paid to the COO in cash and the remainder will continue to accrue. Upon the closing of a capital raise of at least $2,000,000,
the entire monthly fee will be paid to the COO in cash and all accrued and unpaid monthly fees will be paid by the Company within
one year of the closing of such a capital raise. As of the effective date, the Company shall issue to the COO an aggregate of 2,409,000
shares of the Company’s common stock which vest as follows:
1.
409,000 shares on the first-year anniversary of the effective date;
2.
800,000 shares on the second-year anniversary of the effective date; and
3.
1,200,000 shares on the third-year anniversary of the effective date.
The shares are issued under the 2017 Stock
Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change
of Control (as defined in the agreement) or the listing of the Company’s common stock on a senior exchange.
On March 11, 2019, the Company’s
Board of Directors approved the Amended and Restated Consulting Agreement dated effective April 23, 2018 with its CTO. The term
of the agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement and
is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by the CTO pursuant
to the agreement are those customary for the position in which the CTO is serving. The CTO shall receive a monthly fee of $9,375
which accrues unless converted into shares of common stock of the Company at a conversion rate specified in the agreement. Until
the Company closes a minimum $500,000 capital raise, the monthly fee accrues and, upon the closing of such a capital raise, $3,125
of the monthly fee will be paid to the CTO in cash and the remainder will continue to accrue. Upon the closing of a capital raise
of at least $2,000,000, the entire monthly fee will be paid to the CTO in cash and all accrued and unpaid monthly fees will be
paid by the Company within one year of the closing of such a capital raise. As of the effective date, the Company shall issue to
the CTO an aggregate of 1,800,000 shares of the Company’s common stock which vest as follows:
1.
300,000 shares on the first-year anniversary of the effective date;
2.
600,000 shares on the second-year anniversary of the effective date; and
3.
900,000 shares on the third-year anniversary of the effective date.
9. STOCKHOLDERS' EQUITY
Common Stock
The Company has authorized 190,000,000
shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock. At December 31, 2018 and 2017
the Company had 40,633,327 and 38,983,327 shares of common stock and no shares of preferred stock issued and outstanding, respectively.
Holders of shares of common stock are entitled
to one vote for each share on all matters to be voted on by the stockholders. Holders of common stock do not have cumulative voting
rights. Holders of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the
Board of Directors in its discretion from funds legally available, therefore. In the event of liquidation, dissolution, or winding
up of the Company, the holders of common stock are entitled to share pro rata in all assets remaining after payment in full of
all liabilities. All of the outstanding shares of common stock are fully paid and non-assessable. Holders of common stock have
no preemptive rights to purchase the Company’s common stock. There are no conversion or redemption rights or sinking fund
provisions with respect to the common stock.
On March 16, 2017, the Board of Directors
of IIOT-OXYS, Inc. and a majority of the shareholders of IIOT-OXYS, Inc. approved the IIOT-OXYS, Inc. 2017 Stock Awards Plan,
(the “
Plan
”). The Plan provided for granted incentive stock options, options that do not constitute incentive
stock options, stock appreciation rights, restricted stock awards, phantom stock awards, or any combination of the foregoing,
as is best suited to the particular circumstances. The Plan was effective upon its adoption by the Board.
The aggregate number of common shares that
may be issued under the Plan were 7,000,000 common shares. No further awards were to be granted under the Plan after ten years
following the effective date. The Plan was to remain in effect until all awards granted under the Plan had been satisfied or expired.
This Plan was terminated and replaced by the 2017 Stock Inventive Plan (the “
2017 Plan
”) on December 14, 2017
(the “
Effective Date
”) as approved by the Board of Directors of the Company.
Awards may be made under the 2017 Plan
for up to 4,500,000 shares of common stock of the Company. All of the Company’s employees, officers and directors, as well
as consultants and advisors to the Company are eligible to be granted awards under the 2017 Plan. No awards can be granted under
the 2017 Plan after the expiration of 10 years from the Effective Date, but awards previously granted may extend beyond that date.
Awards may consist of both incentive and non-statutory options, restricted stock units, stock appreciation rights, and restricted
stock awards. With the approval of the 2017 Plan, the Board terminated the 2017 Stock Awards Plan with no awards having been granted
thereunder.
On March 11, 2019 (the “
Effective
Date
”) the Board of Directors of the Company approved the 2019 Stock Incentive Plan (the “
Plan
”).
Awards may be made under the Plan for up to 5,000,000 shares of common stock of the Company. All of the Company’s employees,
officers and directors, as well as consultants and advisors to the Company are eligible to be granted awards under the Plan. No
awards can be granted under the Plan after the expiration of 10 years from the Effective Date but awards previously granted may
extend beyond that date. Awards may consist of both incentive and non-statutory options, restricted stock units, stock appreciation
rights, and restricted stock awards.
Shares earned and issued related to the
five consulting agreements discussed in Note 8 are issued under the 2017 Stock Incentive Plan and the 2019 Stock Incentive Plan.
Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as
defined in the agreement) or the listing of the Company’s common stock on a senior exchange.
A summary of the status of the Company’s
non-vested shares as of December 31, 2018 and changes during the year then ended, is presented below:
|
|
Non-vested Shares of Common Stock
|
|
|
Weighted Average Fair Value
|
|
Balance at December 31, 2017
|
|
|
–
|
|
|
$
|
–
|
|
Awarded
|
|
|
7,573,673
|
|
|
|
0.30
|
|
Vested
|
|
|
(104,673
|
)
|
|
|
0.30
|
|
Balance at December 31, 2018
|
|
|
7,469,000
|
|
|
$
|
0.30
|
|
As of December 31, 2018, there was $1,854,873
of total unrecognized compensation costs related to the non-vested share-based compensation arrangements awarded to directors,
engineers, and consultants. That cost is expected to be recognized over a weighted-average period of 2.5 years. The total fair
value of shares vested during the year ended December 31, 2018 was $417,229. Total share-based compensation for the years ended
December 31, 2018 and 2017 was $449,729 and $995,500, respectively.
10. EARNINGS PER SHARE
The following table sets forth the computation
of basic and diluted net loss per share of common stock for the years ended December 31, 2018 and 2017:
|
|
Year ended
December 31,
|
|
|
|
2018
|
|
|
2017
|
|
Net loss attributable to common stockholders (basic)
|
|
$
|
(1,613,299
|
)
|
|
$
|
(1,531,095
|
)
|
|
|
|
|
|
|
|
|
|
Shares used to compute net loss per common share, basic and diluted
|
|
|
40,601,683
|
|
|
|
36,241,821
|
|
|
|
|
|
|
|
|
|
|
Net loss per share attributable to common stockholders, basic and diluted
|
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
Basic net loss per share is calculated
by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share
is computed by dividing net loss by the weighted-average number of common shares and common share equivalents outstanding for the
period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities
which include stock options, convertible preferred stock and common stock warrants have been excluded from the computation of diluted
net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used
to compute basic and diluted shares outstanding due to the Company’s net loss position.
The following outstanding common stock
equivalents have been excluded from diluted net loss per common share for the years ended December 31, 2018 and 2017 because their
inclusion would be ant-dilutive:
|
|
December 31, 2018
|
|
|
December 31, 2017
|
|
Warrants to purchase common stock
|
|
|
384,615
|
|
|
|
–
|
|
11. CONVERTIBLE NOTE PAYABLE
On January 18, 2018, the Board of Directors
of the Company approved a non-public offering of up to $1,000,000 aggregate principal amount (the “
Offering
”)
of its 12% Senior Secured Convertible Notes (the “
Notes
”). The Notes are convertible, in whole or in part, into
shares of the Company’s common stock, at any time at a rate of $0.65 per share with fractions rounded up to the nearest whole
share, unless paid in cash at the Company’s election. The Notes bear interest at a rate of 12% per annum and interest payments
will be made on a quarterly basis. The Notes mature January 15, 2020.
The Notes are governed by a Securities
Purchase Agreement (the “
SPA
”) and are secured by all of the assets of the Company pursuant to a Security and
Pledge Agreement. In addition to the issuance of the Notes in the Offering, the Company’s Board of Directors approved, as
part of the Offering, the issuance of warrants to purchase one share of the Company’s common stock for 50% of the number
of shares of common stock issuable upon conversion of each Note (the “
Warrants
”). Each Warrant is immediately
exercisable at $0.75 per share, contains certain anti-dilution down-round features and expires on January 15, 2023. If the Company
ever defaults on the loan the Warrants to be issued will increase from 50% of the number of shares of common stock issuable upon
conversion to 100%.
On January 22, 2018, the Company entered
into a SPA and Security and Pledge Agreement with its first investor in the Offering and issued a Note to the investor in the principal
amount of $500,000. Subscription funds were received by the Company from the investor on February 7, 2018. In addition to the Note,
the Company issued to the investor 384,615 Warrants. The Warrants are considered equity instruments based on the Company’s
early adoption of ASU 2017-11.
The proceeds received upon issuing the
Note and Warrants were allocated to each instrument on a relative fair value basis. The initial fair value of the Warrants was
$838,404 determined using the Black-Scholes valuation model with the following assumptions: expected term of 2.5 years; risk free
interest rate of 2.1%; and volatility of 142%. The effective conversion rate resulted in a Beneficial Conversion Feature greater
than the proceeds received. Thus, the discount is limited to the proceeds received of $500,000 and is amortized to interest expense
using the effective interest method over the term of the Note.
For the year ended December 31, 2018 interest
expense paid to the investor amounted to $56,384. For the year ended December 31, 2018 the Company also amortized to interest expense
$234,932 from the amortization of the discount.
The unpaid principal balance of the Note
is $500,000 at December 31, 2018 and the remaining unamortized discount is $265,068.
12. RELATED PARTIES
At December 31, 2018 and 2017 the amount
due to stockholders was $1,000. The balance is payable to two stockholders related to opening bank balances.
At December 31, 2018 and 2017 accounts
payable due to three officers was $237,514 and $0, respectively. The majority of the balance is related to deferred salary expenses
while the remainder is related to reimbursable expenses that were incurred throughout the year.
In August 2017 the Company entered into
a lease agreement with a stockholder of the Company and paid monthly installments of $2,000 between August and December 2017. The
Company entered into a second lease agreement which began on January 1, 2018 and terminated on December 31, 2018. The Company paid
the landlord monthly installments of $2,000. For the years ended December 31, 2018 and 2017, rent expense paid to the stockholder
amounted to $24,000 and $10,000, respectively.
The Company entered into a verbal arrangement
with a company controlled by a shareholder to provide administrative services. Total payments to the related party for administrative
services amounted to approximately $26,000 and approximately $33,000, for the years ended December 31, 2018 and 2017, respectively.
For the years ended December 31, 2018 and
2017, professional expense paid to directors and officers of the Company amounted to approximately $130,000 and $40,000, respectively.
For the years ended December 31, 2018 and 2017, travel expense paid on behalf of directors and officers of the Company amounted
to approximately $8,000 and $5,000, respectively.
13. SUBSEQUENT EVENTS
The Company has evaluated subsequent events
from the balance sheet date through the date the financial statements were issued and determined to disclose the following:
On January 10, 2019, the Company entered
into a Strategic Advisory Agreement with a consultant. The initial term of the agreement is 90 days from the date of the agreement
and will be renewed for an additional 90-day term unless either party gives written notice at least ten days prior to the expiration
of the initial term. Pursuant to the agreement, the consultant will provide the Company consulting services pertaining to strategic
planning for marketing and capital raising. In consideration of receipt of the services, the Company will issue to the consultant
$25,000 worth of shares of the Company’s common stock within three business days of the beginning of each month of the initial
term and the additional term if the Agreement is not terminated prior. The calculation of the shares to be issued each month is
based on the average closing price of the three days prior for each month during which the agreement is in effect.
On January 22, 2019, the Company entered
into a Securities Purchase Agreement and Security and Pledge Agreement with a single investor and issued a Secured Convertible
Promissory Note to the investor in the principal amount of $55,000. $54,000 of the subscription funds were received by the Company
from the investor on February 5, 2019 and February 8, 2019. $1,000 of the subscription funds were received by the Company from
the investor on March 26, 2019. In addition to the note, the Company issued to the investor 36,667 warrants.
On March 7, 2019, the Board of Directors
of the Company approved Amendment No. 1 to the 12% Senior Secured Convertible Promissory Note and the Warrant Agreement, each issued
January 22, 2018, respectively, to a note holder. The amendments (i) extend the maturity date of the note to March 1, 2021 and
extend the term of the warrants to March 6, 2024, (ii) lower the conversion price of the note and the exercise price of the warrants
to $0.20 and $0.30, respectively, and (iii) add an adjustment to the conversion and exercise price of the note and warrants, respectively,
in the event the Company does not achieve certain milestones during calendar 2019.
On March 7, 2019, the Board of Directors
of the Company approved the Financial Consulting Agreement dated effective March 4, 2019 with a consultant pursuant to which the
Company agreed to issue to the consultant 500,000 shares of the Company’s common stock in exchange for consulting services
provided by the consultant to the Company. The term of the agreement is six months, unless terminated earlier.
On March 7, 2019, the Board of Directors
of the Company approved a non-public offering of up to $500,000 aggregate principal amount of its 12% Senior Secured Convertible
Notes. The notes are convertible, in whole or in part, into shares of the Company’s common stock, at any time at a rate of
$0.20 per share with fractions rounded up to the nearest whole share, unless paid in cash at the Company’s election. The
notes bear interest at a rate of 12% per annum and interest payments will be made on a quarterly basis. The notes mature March
1, 2021. The conversion price of the notes is also subject to adjustments if the Company does not achieve certain milestones during
the calendar year 2019.
The notes are governed by a Securities
Purchase Agreement (the “
SPA
”) and are secured by all the assets of the Company pursuant to a Security and Pledge
Agreement. Funding is subject to the occurrence of certain milestones, as stated in the SPA. In addition to the issuance of the
notes in the offering, the Company’s Board of Directors approved, as part of the offering, the issuance of warrants to purchase
one share of the Company’s common stock for 50% of the number of shares of common stock issuable upon conversion of each
note. Each warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date.
On March 6, 2019, the Company entered
into SPAs and Security and Pledge Agreements with its first two investors in the offering and issued notes to the investors in
the aggregate principal amount of $100,000. Subscription funds were received by the Company from the investors on March 6, 2019.
In addition to the notes, the Company issued to the investors an aggregate of 250,000 warrants.
[OUTSIDE BACK COVER]
IIOT-OXYS, Inc.
[A Nevada Corporation]
34,673,202 Shares
Common Stock
PROSPECTUS
IIOT-OXYS,
INC.
705 Cambridge Street
Cambridge, MA 02141
Telephone (617) 500-5101
_______________, 2019
Until ,
2019, all dealers that effect transactions in our shares, whether or not participating in this offering, may be required to deliver
a prospectus. This is in addition to the dealer’s obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions.
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution
The following is an itemized statement
of the estimated amounts of all expenses payable by us in connection with the registration of the common stock, other than underwriting
discounts and commissions. All amounts are estimates except the SEC registration fee.
Securities and Exchange Commission - Registration Fee
|
|
$
|
5,397
|
|
Edgarizing Costs
|
|
|
3,000
|
|
Accounting Fees and Expenses
|
|
|
10,000
|
|
Legal Fees and Expenses
|
|
|
10,000
|
|
Miscellaneous
|
|
|
3,652
|
|
Total
|
|
$
|
32,049
|
|
None of the expenses of the offering will
be paid by the selling security holders.
Item 14. Indemnification of Directors and Officers
Nevada law expressly authorizes a Nevada
corporation to indemnify its directors, officers, employees, and agents against liabilities arising out of such persons’
conduct as directors, officers, employees, or agents if they acted in good faith, in a manner they reasonably believed to be in
or not opposed to the best interests of the company, and, in the case of criminal proceedings, if they had no reasonable cause
to believe their conduct was unlawful. Generally, indemnification for such persons is mandatory if such person was successful,
on the merits or otherwise, in the defense of any such proceeding, or in the defense of any claim, issue, or matter in the proceeding.
In addition, as provided in the articles of incorporation, bylaws, or an agreement, the corporation may pay for or reimburse the
reasonable expenses incurred by such a person who is a party to a proceeding in advance of final disposition if such person furnishes
to the corporation an undertaking to repay such expenses if it is ultimately determined that he did not meet the requirements.
In order to provide indemnification, unless ordered by a court, the corporation must determine that the person meets the requirements
for indemnification. Such determination must be made by a majority of disinterested directors; by independent legal counsel; or
by a majority of the shareholders.
Section 9.01 of our Bylaws provides that
we will indemnify and hold harmless each person and his or her heirs and administrators who shall serve at any time hereafter as
a director or officer of the Company from and against any and all claims, judgments and liabilities to which such person shall
become subject by reason of his or her having heretofore or hereafter been a director officer of the Company or by reason of any
action alleged to have heretofore or hereafter been taken or admitted to have been taken by him or her as such director or officer
and shall reimburse each such persons for all legal and other expenses reasonably incurred by him or her in connection with any
such claim or liability, including power to defend such person from all suits or claims as provided for under the laws of the state
of Nevada; provided, however, that no such person shall be indemnified against, or be reimbursed for, any expense incurred in connection
with any claim or liability arising out of his or her negligence or willful misconduct.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the
foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 15. Recent Sales of Unregistered Securities
In connection with the closing of the reverse
acquisition on July 28, 2017, we issued an aggregate of 34,687,244 shares of Common Stock to the 45 shareholders of OXYS in exchange
for all of the outstanding common shares of OXYS. Each of these parties was an accredited investor as defined in Rule 501(b) of
Regulation D. Each of the above shareholders delivered appropriate investment representations with respect to the securities issued
at closing and consented to the imposition of restrictive legends upon the stock certificates representing the shares. No shareholder
entered into the transaction with us as a result of or subsequent to any advertisement, article, notice, or other communication
published in any newspaper, magazine, or similar media or broadcast on television or radio, or presented at any seminar or meeting.
Each shareholder was also afforded the opportunity to ask questions of management and to receive answers concerning the terms and
conditions of the reverse acquisition transaction. These securities were issued without registration under the Securities Act by
reason of the exemption from registration afforded by the provisions of Section 4(a)(2) thereof, and Rule 506(b) promulgated thereunder,
as a transaction by an issuer not involving any public offering. No selling commissions were paid in connection with the issuance
of these securities.
Pursuant to the Consulting Agreement dated
October 1, 2017 with DATHNA Partners LLC, we issued 30,000 shares of our Common Stock. The consultant was an accredited investor
as defined in Rule 501(b) of Regulation D. The consultant delivered appropriate investment representations with respect to the
securities issued and consented to the imposition of a restrictive legend upon the stock certificate representing the shares issued.
The consultant did not enter into the transaction with us as a result of or subsequent to any advertisement, article, notice, or
other communication published in any newspaper, magazine, or similar media or broadcast on television or radio, or presented at
any seminar or meeting. The consultant was also afforded the opportunity to ask questions of management and to receive answers
concerning the share issuance. These securities were issued without registration under the Securities Act by reason of the exemption
from registration afforded by the provisions of Section 4(a)(2) thereof, and Rule 506(b) promulgated thereunder, as a transaction
by an issuer not involving any public offering. No selling commissions were paid in connection with the issuance of these securities.
Pursuant to the Consulting Agreement dated
effective December 1, 2017 with Draco Financial LLC, we issued 350,000 shares of our Common Stock and we agreed to issue 150,000
shares of our Common Stock on or before February 15, 2018, as long as the agreement has not been terminated prior to such issuances.
The Consultant is an accredited investor as defined in Rule 501(b) of Regulation D. The consultant has delivered appropriate investment
representations with respect to the securities to be issued and has consented to the imposition of restrictive legends upon the
stock certificates representing the shares to be issued. The consultant did not enter into the transaction with us as a result
of or subsequent to any advertisement, article, notice, or other communication published in any newspaper, magazine, or similar
media or broadcast on television or radio, or presented at any seminar or meeting. The consultant was also afforded the opportunity
to ask questions of management and to receive answers concerning the share issuances. These securities will be issued without registration
under the Securities Act by reason of the exemption from registration afforded by the provisions of Section 4(a)(2) thereof, and
Rule 506(b) promulgated thereunder, as a transaction by an issuer not involving any public offering. No selling commissions will
be paid in connection with the issuances of these securities.
Pursuant to the Closing of the HereLab
SEA on January 11, 2018 we issued 1,650,000 shares of our common stock to two shareholders of HereLab in exchange for the outstanding
ownership of HereLab. The shareholders were accredited investors as defined in Rule 501(b) of Regulation D. The shareholders delivered
appropriate investment representations with respect to the securities issued and consented to the imposition of a restrictive legend
upon the stock certificate representing the shares issued. The shareholders did not enter into the transaction with us as a result
of or subsequent to any advertisement, article, notice, or other communication published in any newspaper, magazine, or similar
media or broadcast on television or radio, or presented at any seminar or meeting. The shareholders were also afforded the opportunity
to ask questions of management and to receive answers concerning the share issuances. These securities were issued without registration
under the Securities Act by reason of the exemption from registration afforded by the provisions of Section 4(a)(2) thereof, and
Rule 506(b) promulgated thereunder, as a transaction by an issuer not involving any public offering. No selling commissions were
paid in connection with the issuance of these securities.
On January 18, 2018, our Board of Directors
approved a non-public offering of up to $1,000,000 aggregate principal amount of its 12% Senior Secured Convertible Notes. The
Notes are convertible, in whole or in part, into shares of our Common Stock, at any time at a rate of $0.65 per share with fractions
rounded up to the nearest whole share, unless paid in cash at our election. The Notes bear interest at a rate of 12% per annum
and interest payments will be made on a quarterly basis. The Notes mature January 15, 2020. The Notes are governed by a Securities
Purchase Agreement and are secured by all of our assets pursuant to a Security and Pledge Agreement. In addition to the issuance
of the Notes in the offering, our Board of Directors approved, as part of the offering, the issuance of warrants to purchase one
share of our Common Stock for 50% of the number of shares of Common Stock issuable upon conversion of each Note. Each Warrant is
immediately exercisable at $0.75 per share and expires on January 15, 2023. On January 22, 2018, we entered into a SPA and Security
and Pledge Agreement with our first investor in the offering and issued a Note to the investor in the principal amount of $500,000.
Subscription funds were received by us from the investor on February 7, 2018. In addition to the Note, we issued to the investor
384,615 Warrants. The investor was an accredited investor as defined in Rule 501(b) of Regulation D. The investor delivered appropriate
investment representations with respect to the securities issued and consented to the imposition of a restrictive legend upon the
warrants and stock certificate(s) representing the conversion shares. The investor did not enter into the transaction with us as
a result of or subsequent to any advertisement, article, notice, or other communication published in any newspaper, magazine, or
similar media or broadcast on television or radio, or presented at any seminar or meeting. The investor was also afforded the opportunity
to ask questions of management and to receive answers concerning the transaction. These securities were issued without registration
under the Securities Act by reason of the exemption from registration afforded by the provisions of Section 4(a)(2) thereof, and
Rule 506(b) promulgated thereunder, as a transaction by an issuer not involving any public offering. No selling commissions were
paid in connection with the issuance of these securities.
On March 7, 2019, our Board of Directors
approved the Settlement Agreement dated effective October 5, 2018 with Adam Casey (the “
Casey Agreement
”) pursuant
to which we agreed to issue to Mr. Casey 65,000 shares of our Common Stock (the “
Casey Shares
”) in exchange
for payment, in full, for consulting services provided by Mr. Casey to us in 2018.
On March 7, 2019, our Board of Directors
approved the Financial Consulting Agreement dated effective March 4, 2019 (the “
Draco Agreement
”) with Draco
Financial LLC, a Florida limited liability company (“
Draco
”) pursuant to which we agreed to issue to Draco 500,000
shares of our Common Stock (the “
Draco Shares
”) in exchange for consulting services provided by Draco to us.
On March 7, 2019, our Board of Directors
approved a non-public offering of up to $500,000 aggregate principal amount (the “
Offering
”) of our 12% Senior
Secured Convertible Notes (the “
Notes
”). The Notes are convertible, in whole or in part, into shares of our
Common Stock, at any time at a rate of $0.20 per share with fractions rounded up to the nearest whole share, unless paid in cash
at our election. The Notes bear interest at a rate of 12% per annum and interest payments will be made on a quarterly basis. The
Notes mature March 1, 2021. The conversion price of the Notes is also subject to adjustments if we do not achieve certain milestones
during the calendar year 2019.
The Notes are governed by a Securities
Purchase Agreement (the “
SPA
”) and are secured by all the assets of the Company pursuant to a Security and Pledge
Agreement. Funding is subject to the occurrence of certain milestones, as stated in the SPA. In addition to the issuance of the
Notes in the Offering, our Board of Directors approved, as part of the Offering, the issuance of warrants to purchase one share
of our Common Stock for 50% of the number of shares of Common Stock issuable upon conversion of each Note (the “
Warrants
”).
Each Warrant is immediately exercisable at $0.30 per share and expires five years from the issuance date.
On March 6, 2019, we entered into SPAs
and Security and Pledge Agreements with our first two investors (the “
Investors
”) in the Offering and issued
Notes to the Investors in the aggregate principal amount of $100,000. Subscription funds were received by us from the Investors
on March 6, 2019. In addition to the Note, we issued to the Investors an aggregate of 250,000 Warrants.
The Mr. Casey, Draco, and the Investors
each delivered appropriate investment representations with respect to the Casey Shares, the Draco Shares, the Notes, and the Warrants
and consented to the imposition of restrictive legends upon the stock certificates representing the Casey Shares, the Draco Shares,
the Notes, the Warrants, and the conversion shares. Mr. Casey, Draco, and the Investors did not enter into their respective transactions
with the Company as a result of or subsequent to any advertisement, article, notice, or other communication published in any newspaper,
magazine, or similar media or broadcast on television or radio, or presented at any seminar or meeting. Each of Mr. Casey, Draco,
and the Investors was also afforded the opportunity to ask questions of management and to receive answers concerning the terms
and conditions of the transaction. The Casey Shares, the Draco Shares, the Notes, and the Warrants were issued without registration
under the Securities Act of 1933, as amended, by reason of the exemption from registration afforded by the provisions of Section
4(a)(2) thereof, and Rule 506(b) promulgated thereunder, as a transaction by an issuer not involving any public offering. No selling
commissions were paid in connection with the issuance of the Casey Shares, the Draco Shares, the Notes, and the Warrants.
Item 16. Exhibits and Financial Statement Schedules
Exhibits
The following exhibits are included with
this prospectus:
Incorporated by Reference
|
Exhibit
Number
|
|
Exhibit Description
|
|
Form
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
|
Filed Here-
with
|
2.1 & 10.1
|
|
Securities Exchange Agreement dated March 16, 2017, by and among Gotham Capital Holdings, Inc., OXYS Corp. and the Shareholders of OXYS Corp.
|
|
8-K
|
|
000-50773
|
|
2.1
|
|
8/3/17
|
|
|
2.2 & 10.2
|
|
Agreement and Plan of Merger dated July 10, 2017
|
|
8-K
|
|
000-50773
|
|
2.1
|
|
11/1/17
|
|
|
2.3 & 10.3
|
|
Securities Exchange Agreement dated December 14, 2017, with HereLab, Inc.
|
|
8-K
|
|
000-50773
|
|
2.1
|
|
12/19/17
|
|
|
3.1
|
|
Nevada Articles of Incorporation for IIOT-OXYS, Inc.
|
|
8-K
|
|
000-50773
|
|
3.1
|
|
11/1/17
|
|
|
3.2
|
|
Bylaws for IIOT-OXYS, Inc.
|
|
8-K
|
|
000-50773
|
|
3.2
|
|
11/1/17
|
|
|
3.3
|
|
Nevada Articles of Merger dated July 14, 2017
|
|
8-K
|
|
000-50773
|
|
3.3
|
|
11/1/17
|
|
|
3.4
|
|
New Jersey Certificate of Merger dated October 26, 2017
|
|
8-K
|
|
000-50773
|
|
3.4
|
|
11/1/17
|
|
|
3.5
|
|
Articles of Exchange
|
|
8-K
|
|
000-50773
|
|
2.1
|
|
1/12/18
|
|
|
4.1 & 10.4*
|
|
2017 Stock Incentive Plan
|
|
8-K
|
|
000-50773
|
|
4.1
|
|
12/19/17
|
|
|
4.2 & 10.5*
|
|
2019 Stock Incentive Plan
|
|
8-K
|
|
000-50773
|
|
4.1
|
|
3/12/19
|
|
|
5.1
|
|
Opinion re Legality of Shares
|
|
|
|
|
|
|
|
|
|
X
|
10.6
|
|
Non-Exclusive Patent License Agreement with MIT dated February 5, 2018
|
|
10-K
|
|
000-50773
|
|
10.7
|
|
4/17/18
|
|
|
10.7
|
|
Technology Cooperation Agreement with Sigma Labs, Inc. dated effective June 13, 2017
|
|
10-K
|
|
000-50773
|
|
10.8
|
|
4/17/18
|
|
|
10.8
|
|
Form of 12% Senior Secured Convertible Note
|
|
8-K
|
|
000-50773
|
|
99.1
|
|
2/13/18
|
|
|
10.9
|
|
Form of Securities Purchase Agreement
|
|
8-K
|
|
000-50773
|
|
99.2
|
|
2/13/18
|
|
|
10.10
|
|
Form of Security and Pledge Agreement
|
|
8-K
|
|
000-50773
|
|
99.3
|
|
2/13/18
|
|
|
10.11
|
|
Form of Warrant
|
|
8-K
|
|
000-50773
|
|
99.4
|
|
2/13/18
|
|
|
10.12
|
|
Amendment No. 1 to the 12% Senior Secured Convertible Promissory Note Issued to Sergey Gogin on January 22, 2018
|
|
8-K
|
|
000-50773
|
|
99.3
|
|
3/12/19
|
|
|
10.13
|
|
Amendment No. 1 to the Warrant Agreement Issued to Sergey Gogin on January 22, 2018
|
|
8-K
|
|
000-50773
|
|
99.4
|
|
3/12/19
|
|
|
10.14
|
|
Form of 12% Senior Secured Convertible Note
|
|
8-K
|
|
000-50773
|
|
99.5
|
|
3/12/19
|
|
|
10.15
|
|
Form of Securities Purchase Agreement
|
|
8-K
|
|
000-50773
|
|
99.6
|
|
3/12/19
|
|
|
10.16
|
|
Form of Security and Pledge Agreement
|
|
8-K
|
|
000-50773
|
|
99.7
|
|
3/12/19
|
|
|
10.17
|
|
Form of Warrant
|
|
8-K
|
|
000-50773
|
|
99.8
|
|
3/12/19
|
|
|
10.18*
|
|
Consulting Agreement with Patrick Phillips dated August 22, 2017
|
|
10-K
|
|
000-50773
|
|
10.13
|
|
4/17/18
|
|
|
10.19*
|
|
Consulting Agreement with Patrick Phillips dated May 22, 2018
|
|
S-1/A
|
|
333-222311
|
|
10.17
|
|
6/8/18
|
|
|
10.20*
|
|
Settlement Agreement with Patrick Phillips dated November 5, 2018
|
|
10-K
|
|
000-50773
|
|
10.20
|
|
4/16/19
|
|
|
10.21*
|
|
Consulting Agreement with Antony Coufal dated April 23, 2018
|
|
8-K
|
|
000-50773
|
|
99.1
|
|
5/4/18
|
|
|
10.22*
|
|
Amendment No. 1 to the Consulting Agreement with Antony Coufal dated October 9, 2018
|
|
8-K
|
|
000-50773
|
|
99.2
|
|
10/11/18
|
|
|
10.23*
|
|
Amended and Restated Consulting Agreement with Antony Coufal dated effective April 23, 2018
|
|
8-K
|
|
000-50773
|
|
99.11
|
|
3/12/19
|
|
|
10.24*
|
|
Consulting Agreement with Accelerated Health Care Innovations LLC dated December 1, 2017
|
|
S-1/A
|
|
333-222311
|
|
10.15
|
|
6/8/18
|
|
|
10.25*
|
|
Consulting Agreement with Accelerated Health Care Innovations LLC dated March 1, 2018
|
|
S-1/A
|
|
333-222311
|
|
10.16
|
|
6/8/18
|
|
|
10.26*
|
|
Amendment No. 1 to Consulting Agreement with Accelerated Health Care Innovations LLC dated December 1, 2018
|
|
8-K
|
|
000-50773
|
|
99.1
|
|
8/1/18
|
|
|
10.27*
|
|
Amendment No. 1 to Consulting Agreement with Accelerated Health Care Innovations LLC dated December 1, 2018
|
|
8-K
|
|
000-50773
|
|
99.2
|
|
8/1/18
|
|
|
10.28*
|
|
Termination Agreement with Accelerated Health Care Innovations LLC dated July 31, 2018
|
|
8-K
|
|
000-50773
|
|
99.3
|
|
8/1/18
|
|
|
10.29*
|
|
Consulting Agreement with Clifford Emmons dated effective June 4, 2018
|
|
8-K
|
|
000-50773
|
|
99.9
|
|
3/12/19
|
|
|
10.30*
|
|
Consulting Agreement dated July 1, 2018 with Karen McNemar
|
|
10-Q
|
|
000-50773
|
|
10.1
|
|
11/9/18
|
|
|
10.31*
|
|
Consulting Agreement with Karen McNemar dated effective October 1, 2018
|
|
8-K
|
|
000-50773
|
|
99.10
|
|
3/12/19
|
|
|
10.32*
|
|
Amendment No. 1 to the Consulting Agreement with Karen McNemar dated October 5, 2018
|
|
8-K
|
|
000-50773
|
|
99.1
|
|
10/11/18
|
|
|
10.33
|
|
Consulting Agreement with DATHNA Partners LLC dated October 1, 2017
|
|
S-1/A
|
|
333-222311
|
|
10.18
|
|
6/8/18
|
|
|
10.34
|
|
First Amendment to Consulting Agreement with DATHNA Partners LLC dated effective October 1, 2017
|
|
S-1/A
|
|
333-222311
|
|
10.19
|
|
6/8/18
|
|
|
10.35
|
|
Financial Consulting Agreement with Draco Financial LLC dated effective December 1, 2017
|
|
S-1/A
|
|
333-222311
|
|
10.20
|
|
6/8/18
|
|
|
10.36
|
|
Financial Consulting Agreement with Draco Financial LLC dated effective March 4, 2019
|
|
8-K
|
|
000-50773
|
|
99.2
|
|
3/12/19
|
|
|
10.37
|
|
Subconsultant Agreement for Professional Services dated effective February 21, 2018 with Gill Engineering Associates, Inc.
|
|
S-1/A
|
|
333-222311
|
|
10.24
|
|
8/6/18
|
|
|
10.38
|
|
Purchase Order dated May 16, 2018 with Madison Electric
|
|
S-1/A
|
|
333-222311
|
|
10.25
|
|
8/6/18
|
|
|
10.39
|
|
Securities Purchase Agreement with Cambridge MedSpace, LLC dated January 22, 2019
|
|
8-K
|
|
000-50773
|
|
99.1
|
|
1/23/19
|
|
|
10.40
|
|
5% Convertible Secured Note with Cambridge MedSpace, LLC dated January 22, 2019
|
|
8-K
|
|
000-50773
|
|
99.2
|
|
1/23/19
|
|
|
10.41
|
|
Security Agreement with Cambridge MedSpace, LLC dated January 22, 2019
|
|
8-K
|
|
000-50773
|
|
99.3
|
|
1/23/19
|
|
|
10.42
|
|
Warrant Agreement with Cambridge MedSpace, LLC dated January 22, 2019
|
|
8-K
|
|
000-50773
|
|
99.4
|
|
1/23/19
|
|
|
Item 17. Undertakings
The undersigned registrant hereby undertakes:
(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:
(i) Include
any prospectus required by section 10(a)(3) of the Securities Act;
(ii) Reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high and of the estimated
maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation
of Registration Fee” table in the effective registration statement.
(iii) Include
any material or changed information with respect to the plan of distribution not previously disclosed in the registration statement
or a material change to such information in the registration statement.
(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4) Each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness.
Provided
,
however
, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use.
(5) That,
for the purpose of determining liability under the Securities Act to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424 of Regulation C of the Securities Act;
(ii) Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;
(iii) The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv) Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is
against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person
of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this amended registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the city of Cambridge, Massachusetts, on April 29, 2019.
|
IIOT-OXYS, Inc.
|
|
|
|
By:
/s/ Clifford L. Emmons
______________________________
|
|
Clifford L. Emmons, CEO
|
|
|
Pursuant to the requirements of the Securities
Act of 1933, this amended registration statement has been signed by the following persons in the capacities and on the dates stated.
Name
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Clifford L. Emmons
|
|
Director, CEO, President & Interim CFO
|
|
April 29, 2019
|
Clifford L. Emmons
|
|
(Principal Executive Officer and Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Vidhydhar Mitta
|
|
Director
|
|
April 29, 2019
|
Vidhydhar Mitta
|
|
|
|
|
|
|
|
|
|
IIOT OXYS (PK) (USOTC:ITOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IIOT OXYS (PK) (USOTC:ITOX)
Historical Stock Chart
From Sep 2023 to Sep 2024